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Summary 
Background: Patients presenting for emergency psychiatric evaluation have a high 
prevalence of combined medical and psychiatric illness and psychoactive substance use. This 
comorbidity causes differential diagnostic challenges and deserves careful attention. 
Detection of recent substance intake, which may be required for appropriate diagnosis and 
intervention, can be based upon clinical assessment, patients’ self-report or toxicological 
analyses. There is, however, no consensus on how this assessment should be performed, and 
the utility of laboratory analyses has not been widely evaluated. Also, estimates of 
psychoactive substance use among acutely admitted psychiatric patients vary among studies, 
and few have used comprehensive laboratory methods.  
Objectives: The first main objective was to identify the rates of psychoactive substance use 
and drug influence among patients admitted to acute psychiatric wards, by using 
chromatography-based analyses of blood and urine. The second objective was to investigate 
associations between substance use and various clinical variables, and the third was to 
compare physician assessment and on-site urine testing with the results of comprehensive 
toxicological analyses.  
Methods: A cross-sectional and laboratory-based pilot study was conducted in 2003 in Oslo, 
Norway. The study sample comprised 100 acute psychiatric admissions (86% of all 
consecutive admissions in the project period). Blood and urine samples were collected as soon 
as possible after admission and extensively analyzed for alcohol, medicinal and illegal drugs, 
and drug influence at the time of admission was estimated on the basis of blood drug 
concentrations. The main study was conducted in 2006/2007, in two psychiatric departments 
situated in Oslo and Arendal, Norway. The study sample comprised 309 consecutive 
admissions in Oslo (88% of all) and 47 (42%) in Arendal. Blood and urine samples were 
collected and analyzed for alcohol, medicinal and illegal drugs, and a routine on-site urine 
screening test was performed in 92 of the cases. At admission, the physician on call 
performed an overall judgment of recent drug intake and of current drug influence. Psychotic 
symptoms were assessed with the positive subscale of the Positive and Negative Syndrome 
Scale. Patient self-report questionnaires included the Alcohol and Drug Use Disorder 
Identification Tests. Both patients and physicians were asked if they thought that the 
admission was related to substance use, and patients were also asked if they needed 
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professional help for substance use. Sociodemographic variables, clinical characteristics and 
medication history were obtained through the review of medical records. 
Results: In the pilot study, psychoactive substances were detected in 63% of the 100 
admissions, medicinal drugs in 47%, alcohol in 8% and illegal drugs in 36%. On the basis of 
blood drug concentrations, drug influence was estimated in 26% of the patients. In the main 
study, similar rates were found: Substances were detected in 63% of the 298 admissions, 
medicinal drugs in 46%, alcohol in 12% and illegal drugs in 28%. A total of 20 different 
substances were identified, with up to 10 in a single patient. Nonprescribed use of medicinal 
drugs was found for 36% of patients. Patients using alcohol had a high suicidal risk score at 
admission and the shortest length of stay (median one day). Use of illegal drugs was 
associated with psychotic symptoms and readmission. Self-report questionnaires indicated 
harmful use of alcohol for half of the patients and of other substances for one-third. A need 
for professional help for substance use was reported by one-third of patients. When 
comparing clinical and laboratory data, our findings indicated clinical under-detection of 
recent substance intake. On-site urine testing identified substance use that was not recognized 
by the physician’s initial assessment, although specificity for cannabis and benzodiazepines 
was low. Finally, patients were judged by the physician as being under the influence of drugs 
and/or alcohol in 28% of the cases. The clinical assessment of drug influence showed a 
moderate positive relationship with the blood drug concentration scores, and also to 
symptoms of hyperactivity/agitation and to the detection of alcohol, cannabis and 
amphetamines.    
Conclusion: Our findings demonstrate the major impact of both recent and long-term 
substance use. Given the high rates of substance use and the important clinical associations, 
drug screening seems warranted in acute psychiatric settings. Chromatographic urine analyses 
should be considered for routine screening, and clinical staff using on-site urine screening 
tests should be aware of their inaccuracy. Also, interventions designed for substance-using 
patients should be developed and integrated.    
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Definitions 
In literature dealing with mental health and substance use, there is a wide variation in 
phenomenology, methodology and terminology. In this thesis, the following definitions are 
used:  
“Mental disorders” and “substance use disorders” are defined according to the standard 
nomenclature of the International Classification of Diseases (ICD-10), chapter F0-F9 (1). The 
criteria for the main substance use disorders are given in Table 1.  
 “Comorbidity” refers to a person having co-occurring mental disorder and substance use 
disorder.  
“Severe mental illness” refers to major mental disorders such as schizophrenia, severe bipolar 
disorder and severe depression, with loss of daily function and persistence over time (2).  
 “Acute psychiatric admission” will refer to persons being admitted for inpatient assessment 
and treatment in acute psychiatric wards for adults. Many of these patients have severe mental 
illnesses. The patient may, however, present with a wide range of problems and does not 
necessarily fulfill the criteria for any mental disorder.  
“Psychiatric emergency department” will refer to an out-patient department for the assessment 
and treatment of patients with acute psychiatric conditions.  
The words “substance” and “drug” are used as synonyms, and will both refer to psychoactive 
substances including benzodiazepines, opioids, alcohol, amphetamines, cocaine, cannabis and 
hallucinogens. The study is laboratory based, and all the specific substances that were 
included in the analyses are described in chapter 4.1. These substances can be classified on 
the basis of their primary effect (sedatives, stimulants and hallucinogens) or on their legal 
status (medicinal drugs, alcohol and illegal drugs), and may be used recreationally to 
purposefully alter one's consciousness or therapeutically as medication. 
“Recent substance intake” will mostly refer to substances taken during the previous few days 
before admission, and is not necessarily a part of a substance use disorder. 
“Drug influence” will refer to the acute and impairing effects of substance intake, as measured 
by clinical assessment or by blood drug analyses.  

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Table 1 Selected substance use disorders according to ICD-10 (condensed) (1). The criteria are applied for 
substances individually.   
ICD-10; International Classification of Diseases.  
 

ICD-10 diagnoses  
Acute intoxication 
    There must be clear evidence of recent use at sufficiently high doses 
    Symptoms or signs of intoxication compatible with the known actions of the particular substance  
    Not accounted for by a medical disorder or by another mental disorder 
Harmful use 
    Substance-induced psychological or physical harm 
    Pattern of use persisted for at least 1 month or has occurred repeatedly within 1 year 
Dependence (at least 3) 
    Compulsion to use 
    Impaired control 
    Withdrawal state when substance use is reduced or ceased     
    Tolerance development 
    Substance use prioritized over other activities 
    Continued use despite harmful consequences 
Withdrawal state 
    Recent cessation or reduction of substance use after repeated and prolonged use 
    Symptoms and signs compatible with the known features of a withdrawal state from the particular substance 
    Not accounted for by a medical disorder or by another mental disorder 
Substance-induced psychotic disorders 
    Onset of psychotic symptoms must occur during or within 2 weeks of substance use 
    Psychotic symptoms must persist for more than 48 hours 
    Must not exceed 6 months 

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1. Introduction  
About 450 million people worldwide are affected by mental disorders (3). In 2005, mental 
disorders comprised 14% of the global burden of disease (4). The figure includes substance 
use disorders and is likely to increase by 2030. This burden has substantial social and 
economic consequences for individuals, families and governments. There is a wide 
international and interregional variation in the organization of mental health services, and 
many developing countries lack such services (3).  
In many European countries and in the USA, mental health services have been de-
institutionalised over the last decades. This has resulted in a shift from inpatient care to 
community care (5). Still, inpatient units play an important role in the treatment of many 
psychiatric patients, and hospitals are an essential part of modern psychiatric services, 
demanding significant human and economic resources (6). In most countries, acute wards 
represent a key component of the overall network of mental health services, being the only 
part of the system that cannot refuse to accept a referral (7). Despite the importance of acute 
inpatient care, its quantitative and qualitative features remain largely unexplored (7, 8).  
This thesis focuses on the use and influence of drugs and alcohol among patients admitted to 
acute psychiatric wards in two Norwegian hospitals. Different measurements are applied and 
compared, with an emphasis on comprehensive laboratory analyses and physician assessment. 
The study emerged from clinical practice, and the background was two-fold. First, there was a 
lack of studies documenting the rates of substance use among acute psychiatric admissions in 
Norway. Second, few studies had used comprehensive toxicology analyses internationally, 
and in particular, quantitative blood drug analyses were previously unproven.   
 
1.1.  Acute psychiatric admissions 
System characteristics: 
Countries vary widely with regard to the initial assessment and caretaking of persons with 
acute mental and/or behavioural disturbances. Several institutions can be involved, such as 
primary health care, emergency departments, psychiatric outpatient clinics, substance abuse 
facilities and police. In psychiatric emergency departments, for example, the staff will need to 
determine if the patient needs to be admitted to a psychiatric inpatient facility or if they can be 
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safely discharged to the community after a period of observation and/or brief treatment. Acute 
psychiatric teams, crisis hostels and community health centre beds may also provide 
alternatives to hospitalization (9-11). The decision to hospitalize from emergency departments 
may be related to contextual factors such as site and bed availability (12), but patient factors 
such as suicide potential, danger to others and symptom severity comprise the strongest 
predictors of hospital admission (13, 14).  
Procedures and criteria for hospital admission vary across regions and countries (14). Rates of 
involuntary placement or treatment of people with mental illness are considered to be an 
indicator for the characteristics of national mental health care laws. Among 13 European 
countries not including Norway, the percentage of involuntary admissions in relation to all 
admissions ranged from 3% - 30%, with a median value of 13% (15). In a national study in 
Norway, the rate was 42% and differed greatly across regions (16), and there was also a 
substantial between-ward variance in the use of seclusion, restraint and involuntary 
medication (17). European and US studies also find geographical variations with regard to the 
numbers of admissions and acute beds per 1000 inhabitants, staff/patient ratio and assessment 
and treatment strategies (5, 6, 16, 18-20). These variables may also differ across public and 
private inpatient facilities (21). Mean length of hospital stay has been reported in a few 
national studies, being 10 days in Norway, 12 in Italy and median 15 days in England (5, 6, 
16). Readmissions are common, and in Norway, 57% of patients admitted to acute psychiatric 
wards had at least one other psychiatric admission during the previous year (16). During the 
period of de-institutionalisation, the overall length of stay has declined and the rates of 
admission and pressure on beds have increased (7), and this has raised serious concerns on the 
quality of care (22). 
Patient characteristics: 
Variation across studies and countries is also observed with regard to patient characteristics. 
Multicentre studies in different countries including Norway have reported similar rates of men 
and women (50%) (16, 21, 23), whereas others found that men were admitted more frequently 
than women (5, 24). Mean age of all patients varied from 34 to 42 years (16, 21, 24). Main 
clinical diagnoses at discharge were reported in a few of these studies. According to ICD-10, 
the most common diagnostic groups were F3 affective disorders (range 21%-33%), F2 

13
schizophrenia (24% - 36%), F4 neurotic disorders (4%-14%) and F1 substance use disorders 
(7% - 13%) (16, 21, 23).  
The Norwegian setting: 
As in other Scandinavian countries, the Norwegian health care system is catchment area based 
and publicly funded and provided. Services for alcohol and substance abuse are organized as a 
part of mental health services. In 2005, there were 23 acute psychiatric departments in 
Norway (17). A person may be referred for voluntarily or for compulsory observation of up to 
10 days or for compulsory treatment for a prolonged period of time. There are psychiatric 
emergency departments in Bergen and Oslo (Psykiatrisk Legevakt), and the latter is open 
daily from 16-23 hrs and has a close cooperation with the somatic emergency department 
which also has an inpatient observational unit. 
 
1.1.1. Initial assessment of acute psychiatric conditions 
Patients admitted to psychiatric wards may present with a wide range of socioeconomic 
problems, mental and somatic symptoms and use of psychoactive substances. These 
possibilities deserve careful assessment and differential diagnostic considerations, which are 
some of the key roles of the acute ward and comprise the focus of this thesis.    
The initial assessment of psychiatric patients has been studied by several authors in US 
emergency departments (25-28), and a clinical policy has been developed (29). In a focused 
medical assessment, a medical etiology for the patient’s symptoms is excluded and other 
illness or injury in need for acute care is detected and treated (29). The evaluation involves 
obtaining a history, performing an appropriate physical and mental status examination, and 
testing, when indicated (28). Patients with acute intoxication and withdrawal states must be 
identified and treated. A recent review among emergency department patients concluded that 
on-site urine screening tests were unlikely to have a significant impact on the management of 
the presenting condition (30). 
Less is known about the initial assessment of patients admitted to acute psychiatric wards. 
The need for a medical approach in the psychiatric ward is demonstrated by studies reporting 
unrecognized medical emergencies among psychiatric inpatients (31), as well as high 
prevalences of metabolic syndromes and infectious diseases (32), that also commonly go 
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undetected (33). The utility of routine laboratory screening among acute psychiatric 
admissions has been under debate (34, 35), and there are currently no specific guidelines 
about which somatic or toxicological tests should be routinely done. Electro cardiography and 
chest radiography should not be performed on a routine basis (36, 37), and the utility of 
neuroimaging is under debate (38, 39). 
 
1.1.2. Initial treatment of acute psychiatric conditions 
For acute psychiatric conditions, there is a scarcity of controlled clinical trials. Conditions like 
acute psychosis and agitated behaviour are difficult to study and co-operation from the study 
population is rare. Also, pharmacological studies may not be considered ethical, as many are 
funded by commercial companies and report outcomes that are difficult to interpret for routine 
clinical care (40). Still, selected pharmacological therapies for acute psychosis or agitated 
behaviour have been reviewed (e.g. benzodiazepines and/or antipsychotics), and patients have 
been recruited both in emergency departments and in acute wards (40-42). In clinical practice, 
several psychotropic drugs are commonly combined, despite limited empirical evidence for 
greater effectiveness or safety of such polypharmacy (43, 44). Little is also known about the 
use of pharmacological and physical restraints, seclusion and combination therapies (42), and 
practice guidelines for initial inpatient treatment are lacking. There are, however, 
comprehensive text books for emergency and inpatient psychiatry (45, 46), as well as practice 
guidelines for the assessment and treatment (acute and long-term) for various psychiatric 
conditions. For example, the American Psychiatric Association has guidelines for 
schizophrenia, bipolar disorders, substance use disorders and suicidal behaviours (47).  
The case presentation (Box 1) refers to an actual person and may illustrate some typical 
challenges in the assessment and treatment of acute psychiatric conditions.  
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Box 1 Case presentation 











In December 2004, a 21-year old man (“Joe”) was admitted for the first time to the acute psychiatric ward. He 
was referred from an outpatient clinic for compulsory observation of up to 10 days because of substance use, 
aggressive behaviour and increasing psychotic symptoms. Joe was brought to the ward by police officers.  
At the time of admission, Joe had incoherent speech and disorganized thoughts. He confirmed paranoid ideas, 
use of amphetamines and lack of sleep, but there were no signs of hallucinations. Little was known about his 
background, premorbid functioning and somatic health. Joe was verbally aggressive and did not accept any 
somatic assessment. After a while, he accepted antipsychotic medication and hypnotics, per os, and he soon fell 
asleep. The physician on call noted that this could possibly be a substance induced psychosis. 
After a few days in the locked ward and with a lot of sleep, Joe seemed much calmer and was not aggressive 
any more. He said that he had a difficult childhood, as both his parents had severe substance problems, and that 
he for many years was taken care of by the child protection services. Joe started to smoke cannabis at the age of 
13, and later he started using amphetamines and flunitrazepam. He did not complete primary school and now 
he was unemployed and lived with his mother again. There had been no previous contact with mental health 
services. 
During hospital stay, Joe abstained from substance use and his psychotic symptoms weakened. He said he 
wanted to cut down his substance use and to start outpatient treatment, for which he was referred. At discharge 
after one week, he received the diagnosis of F12.5, cannabis induced psychosis. The clinician noted that 
attention deficit hyperactivity disorder could not be excluded. The diagnosis was based on routine clinical 
practice, and questionnaires, structured interviews or laboratory analyses for psychoactive substances were not 
used. Somatic assessment and brain imaging had not been performed, but blood samples were drawn three days 
after admission, and somatic laboratory analyses were all within the normal ranges.  

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1.2. Mental disorders and co-occurring substance use disorders 
The thesis focuses on substance use among patients admitted to acute psychiatric wards. 
Although such use is not necessarily a part of a substance use disorder, it will here be 
discussed in the context of mental disorders and co-occurring substance use disorders. 
 
1.2.1. Prevalence and consequences of co-occurring substance use disorders 
There is a growing use of psychoactive substances worldwide. In year 2000, there were an 
estimated 2 billion alcohol users, 1.3 billion tobacco users and 185 million drug users, causing 
major global public health problems (48). Alcohol consumption alone comprised nearly 5% of 
the global burden of disease in 2004 (49). Among patients with mental disorders, substance 
use is even more common than in the general population (50, 51). The relation between 
substance use and mental disorders is complex and has been object of extensive research over 
the last two decades, and most studies have focused on substance use disorders.   
The large population of persons with co-occurring disorders is heterogeneous in regard to type 
and severity of mental illness and substance use disorder and cognitive and psychosocial skills 
(2). Patients with severe mental illness in outpatient settings have been particularly studied, 
and a 50% lifetime prevalence of substance use disorders are commonly reported (52). 
Substance use disorders have been associated with several adverse consequences among these 
patients, such as a more severe symptom burden, more frequent hospital admissions, poor 
treatment outcome and increased risk of violent and suicidal behaviour (53-57). It has also 
been suggested that even small amounts of drugs or alcohol may pose problems for patients 
with severe mental illness (58, 59). In contrast, some studies of substance using patients with 
schizophrenia have reported fewer negative symptoms and better social functioning (60, 61). 
Substance use disorders are also highly prevalent among patients with less severe mental 
disorders, and may induce or exacerbate psychiatric symptoms and affect treatment outcome 
negatively (62, 63). For these co-morbid conditions, knowledge on etiology and 
pathophysiology is still limited (52). 
Acute psychiatric admissions 
With regard to substance use disorders among patients admitted to acute psychiatric wards, a 
review of studies published 1989 - 2009 is shown in Table A1 (Appendix) (16, 21, 24, 64-91). 
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In summary, these studies find that current substance use disorders are highly prevalent 
(commonly 40 - 50%) and have adverse clinical implications, such as poorer outcome, higher 
rates of admission and shorter length of hospital stay (73, 77, 79). There are, however, many 
methodological differences between these studies, with regard to study population, sample 
size and definition and measurement of substance use disorders (Table A1).  
 
1.2.2. Assessment of co-occurring substance use disorders 
The large and heterogeneous population of persons with co-occurring mental disorders and 
substance use disorders comprise challenges to diagnostic and treatment strategies. In the 
traditional system of parallel substance abuse treatment and mental health services, few 
patients were able to access needed treatments for both disorders, and the services were rarely 
addressing the common interactive elements of co-occurrence (2). Over the last decades, there 
has been an overall tendency towards assessment and treatment strategies that integrate 
mental health and substance abuse interventions. A comprehensive psychiatric evaluation is 
essential to guide the treatment of a patient with a substance use disorder, as is an evaluation 
of substance use for a patient with a psychiatric disorder (92). For patients with severe mental 
illness and substance use disorders, it has been stated that “assessment is the cornerstone of 
effective treatment” (93). 
Acute psychiatric admissions 
In studies of substance use disorders among patients in acute psychiatric wards, different 
methods have been used (Table A1). Diagnostic interviews are based on the diagnostic 
criteria for mental and substance use disorders and examples are Structured Clinical Interview 
for DSM-IV (SCID) (94) , Psychiatric Research Interview for Substance and Mental 
Disorders (PRISM) (95) and MINI International Neuropsychiatric Interview (96). Non-
diagnostic interviews may also be used, such as the Addiction Severity Index (ASI) (97), and 
may be used to define “problem substance use”. Clinician rated scales (e.g. the Drake scale 
(98)) and self-report questionnaires (e.g. Alcohol Use Disorder Identification Test, AUDIT 
(99))  have been used in several inpatient studies to indicate problem substance use or 
substance use disorders (Table A1).  
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There are, however, several challenges and limitations with these measurements in acute 
psychiatric settings. Little is known about their actual validity and reliability. Structured 
interviews and questionnaires may not be feasible for all patients in an acute psychiatric ward 
(100, 101). Also, diagnostic interviews ideally presuppose that substances were not used 
during the four previous weeks, which rarely is the case among acute admissions with high 
rates of substance use and short length of hospital stay. Few instruments are tailored for acute 
care settings (102), which partly may explain why many studies reported routine clinical 
diagnoses only (Table A1).  
The impact of misdiagnosis has been debated. Under detection of substance use disorders 
have commonly been reported, and the possibility for adequate intervention and follow-up for 
patients with problematic substance use may therefore be lost (73). On the other hand, when 
substance use and psychotic symptoms co-occur, premature use of the label drug induced 
psychosis may obscure the diagnosis of an emerging serious mental illness (82, 103). 
 
1.2.3. Treatment of co-occurring substance use disorders 
Interventions for mental illness and substance use disorder include different treatments and 
rehabilitation (104). Treatments are medications or psychosocial strategies aimed at 
controlling or eliminating the symptoms or causes of illness or disorder; rehabilitation 
interventions are intended to improve skills and supports to enable persons to overcome the 
disabilities associated with illness or disorder. Treatment and rehabilitation overlap 
considerably and are often performed by multidisciplinary teams. 
The effect of pharmacological management among patients with co-occurring disorders is not 
widely evaluated (2). Some medications that are effective for the treatment of alcohol use 
disorders in the general population, such as disulfiram and naltrexone, are probably also 
effective in persons with severe mental illness (105). Also, some medications that treat mental 
illnesses may lead to a reduction of substance use. Antidepressants appear to reduce alcohol 
use among patients with major depression and alcohol disorder (106), as mood stabilizers do 
among patients with bipolar and alcohol use disorder (107). Among persons with 
schizophrenia, atypical antipsychotics may offer some benefit in reducing craving or 
substance use, but research is preliminary (105).    
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Psychosocial treatments for people with co-occurring severe mental illness and substance 
misuse has recently been reviewed, and the results indicate that motivational interviewing can 
be effective for reducing substance use (58). To date, psychosocial treatments for other 
psychiatric populations with substance misuse have not been reviewed. In primary care 
settings, a recent review concluded that brief interventions can reduce alcohol consumption in 
men, with benefit at a year after intervention, but they are unproven in women for whom there 
is insufficient research data (108). The evidence for brief interventions delivered to heavy 
alcohol users admitted to general hospital is also inconclusive (109). A large US study 
performed in various medical settings, however, found that screening and brief interventions 
proved feasible and effective in reducing self-reported use of both alcohol and illegal drugs at 
six months follow-up, along with improved general and mental health and social functioning 
(110).  
Acute psychiatric admissions 
Psychopharmacology, different forms of psychotherapy and a therapeutic milieu are 
cornerstones of the treatment in the acute psychiatric ward. With regard to substance use 
disorders, objectives are e.g. to motivate the patient to change, to reduce the morbidity and 
sequelae of problematic substance use, to provide psycho education to patients and relatives 
and to refer for further treatment in adequate services (104). Motivational interviewing 
appears feasible among psychiatric inpatients, but randomized trials report mixed results. One 
study found that brief motivational interviewing during hospital stay reduced alcohol use at 
six months follow-up (111), whereas another recommended more extensive interventions, 
continuing on an outpatient basis, particularly for cannabis use (112). 
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1.3. Methods for assessing recent substance intake and drug influence  
Of the methods assessing substance use disorders, few assess recent intake and drug 
influence. Typically, drug use is assessed for the previous 30 days (ASI), 6 months (Drake) 
and one year (AUDIT and MINI), and may therefore not be relevant in assessing acute 
conditions. In previous studies, however, recent substance intake and drug influence have 
been assessed by using patient report, physician assessment and laboratory tests.    
 
1.3.1. Patient self-report  
We are not aware of any validated self-report questionnaire that specifically assesses recent 
substance intake. Many studies have therefore included self-made questions addressing recent 
intake as part of questionnaires or interviews in emergency departments (113), acute medical 
settings (114), drug treatment settings (115) and acute psychiatric settings (69, 81, 116, 117). 
Drug use may then be assessed for the previous 6 or 24 hours (118), two days (69), one week 
(117), two weeks (51) or one month (113). However, some validated instruments have an 
indirect measure of recent intake, by assessing the frequency of drug use; for example by 
“every day last month” (ASI).  
 
1.3.2. Physician assessment  
In studies from psychiatric acute care settings, physicians have been asked to judge if the 
patient had been taking any substances recently (76, 90). Clinical assessment of recent drug 
intake is a challenging task, and when compared with laboratory drug findings, these studies 
report significant discrepancies. In a few studies, physicians have assessed whether the acute 
psychiatric admission was related to substance use (119) or substance induced (120, 121). 
“Drug intoxication” in acute psychiatric settings has been defined in different ways, such as 
by any intake of substances last 24 hours (122), by an intentional drug overdose to attempt 
suicide (119) and by an overall clinical judgement (70). “Drug influence” has previously been 
reported in one study only, by using an overall physician assessment (16, 87).  
Also in studies from medical acute care settings, physicians have been asked to judge if the 
patient had been taking any substances recently (123-125). When compared with laboratory 
findings, most studies report significant discrepancies, whereas a few reported better 
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agreement (126, 127). Physicians have also assessed whether the acute medical condition was 
related to substance use (128). In addition, the severity of acute poisoning has been evaluated 
as “not severe, moderate or severe” (123) and consciousness as “awake, somnolent or coma” 
(124). The Glasgow Coma Scale is also widely used as a measure of consciousness in studies 
of acute poisonings (129). We are not aware of any study comparing these clinical 
assessments with quantitative blood drug findings.  
In forensic toxicology, the ability of police physicians to assess recent substance intake and 
drug influence among apprehended has also been studied, using for example the Standardized 
Field Sobriety Test (130) and the Norwegian Clinical Test for Impairment (131). The latter 
test consists of three parts: Substance use history (alcohol and other drugs), clinical 
examination (with simple physical and cognitive tests) and a conclusion on the estimated 
degree of drug influence.  
 
1.3.3. Toxicology methods 
Toxicology methods are widely used for assessing recent substance intake. A comparison of 
some of the different techniques is shown in Table 2 (129). Gas and liquid chromatography-
mass spectroscopy (GC-MS and LC-MS) are the reference standards with high sensitivity and 
specificity. They are useful for quantitation and can have a broad analyte range. These 
methods are however expensive and do not provide immediate, on-site results.   
Table 2 Relative comparison of toxicology methods  
Method Sensitivity Specificity Quantitation Analyte range Speed Cost 
On site test + +/- No Few Fast  £ 
Immunoassay ++ ++ Yes Moderate Medium ££ 
TLC + ++ No Broad Slow ££ 
GC ++ ++ Yes Broad Medium ££ 
GC-MS, LC-MS +++ +++ Yes Broad Slow £££ 
TLC, thin-layer chromatography; GC, gas chromatography; GC-MS, gas chromatography-mass spectroscopy; 
LC-MS, liquid chromatography-mass spectroscopy.  
These toxicological methods can be applied on different biological matrices. Urine has been 
most commonly used both in psychiatric clinical settings and in research. Most drugs can be 
detected in urine for some days after last intake, whereas cannabis can be detected in up to 
several weeks (132). Drug analyses may also be performed in blood, saliva and breath (with 
generally shorter detection times than urine) and hair (detection times up to a year) (129).  
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On-site urine tests are widely used in clinical settings and provide results within 5-10 minutes. 
Many institutions offer immunoassay urine testing for the most commonly abused drugs, and 
results are generally available in 30 minutes. More comprehensive analyses may take up to 
hours or days and are usually performed off-site.   
In clinical toxicology, quantitative blood drug analyses can be used to assess the type and 
severity of intoxications (129), and in forensic toxicology, such analyses are also used to 
estimate the degree of drug influence or impairment (133). Toxicological methods used in 
acute psychiatric settings will be discussed in the next chapter. 
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1.4. Toxicological findings among patients in acute psychiatric services: A 
literature review   
In the following, we will describe studies using toxicological methods among outpatients in 
psychiatric emergency departments and among patients admitted to acute psychiatric wards. 
 
1.4.1. Psychiatric emergency departments 
Among studies of emergency psychiatry and substance use, many have been performed in US 
psychiatric emergency departments (134-141). These studies report urine detection rates of 
“any drug” ranging from 21% - 62%. Most of these studies have reported substance specific 
detection rates by using both immunoassay screening and chromatographic confirmation. We 
have identified one study using blood drug analyses, but quantitative results were not 
presented (122). The latter study concluded that the impact of substance abusing patients was 
substantial; they presented often with acutely suicidal conditions, required high levels of 
behavioural management, spent more time in the emergency department, but had less need for 
psychiatric hospitalization. When laboratory findings were compared with patient and 
physician reports, significant discrepancies were reported in most studies, and better 
agreement in some (141). Some studies concluded in favor of the routine use on-site urine 
screening tests (134, 140), whereas others did not (141). A recent review, however, concluded 
not in favor of using on-site urine tests among emergency department patients (30).  
 
1.4.2. Acute psychiatric admissions  
Detection rates and methodological considerations 
Through a literature review, we identified 20 studies using toxicological analyses among 
patients admitted to acute psychiatric wards from 1970 - 2009 (69, 70, 72, 76, 81, 84-87, 90, 
116, 117, 142-149). These studies report urine detection rates of “any drug” ranging from 
15% - 72% and of “illegal drugs” ranging from 6% - 62% (Table A2, Appendix). These broad 
ranges are partly due to methodological differences. In many studies, sample sizes were small 
and biological specimens were often obtained only for a subgroup of included patients (Table 
A2). All studies were performed in urban settings, but some studies have selected groups of 
patients, such as men (81) or psychotic patients (142). Studies also exhibit variation in the 
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methods used for substance detection. Most studies used qualitative immunological urine 
analyses, whereas five studies did not report which methods were used (76, 85, 87, 145, 146). 
Only four previous studies have used gas or liquid chromatography-mass spectroscopy (81, 
90, 117, 142), of which two included immunological screening (81, 117). Many studies 
lacked detailed information on recent substance intake and polydrug use, and substance 
specific detection rates were reported in about half of the studies (Table A2). Urine samples 
were obtained within 2, 24 or 48 hours after admission, if information about this was reported, 
and blood samples were used in three studies only (87, 116, 142). At the time of admission, 
clinical drug intoxication due to cocaine was reported among 50% of the patients in one study 
(70), and clinical drug influence among one-third of the patients in another (87), but these 
results were not compared with blood drug findings.  
Sociodemographic and clinical associations 
Sociodemographic and clinical associations of biological confirmed substance use among 
psychiatric inpatients have not been widely studied. On the basis of urine drug findings, 
stimulant drug use has been associated with schizophrenia (81) and illegal drug use has been 
associated with men, younger age and precarious housing (116). In three other studies, drug 
users could not be differentiated from non-users on the basis of urine drug findings (69, 76, 
86). Another study used blood drug analyses and found that the methamphetamine 
concentration was partly related to more severe psychotic symptoms (150). 
Under detection 
Studies comparing urine analysis to routine clinical practice, structured interviews and patient 
self-reports have reported under-detection of recent substance intake (65, 66, 81, 116, 117). 
These studies focused on the initial assessment at the time of psychiatric admission. Studies 
among inpatients in a sub-acute phase have reported better agreement between urine findings 
and structured interviews, partly explained by the fact that these patients knew that their 
reports were compared with urine tests (69, 142).  
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1.4.3. Knowledge gaps 
Reviewing previous research among psychiatric inpatients, it seems generally accepted that 
assessment of recent substance intake is important. However, there is no consensus on how 
this assessment should be performed. The utility of laboratory analyses has not been widely 
evaluated, and few previous studies have used comprehensive laboratory methods, including 
both screening and confirmation, for substance detection. On-site urine tests are widely used, 
but few studies have compared them with chromatographic results in an acute psychiatric 
setting. Also, few previous studies have reported data on quantitative blood drug analyses and 
acute drug influence among patients admitted to acute psychiatric wards. 
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2. Objectives 
This cross-sectional study was performed among patients admitted to acute psychiatric wards 
in two Norwegian hospitals. The main objectives were:  
• To identify the rates of psychoactive substance use and drug influence among patients 
admitted to acute psychiatric wards 
• To investigate associations between substance use and various clinical variables 
• To compare physician assessment and on-site urine testing with the results of 
comprehensive toxicological analyses  
The specific research aims were:  
1) To identify rates of recent substance intake among patients admitted to acute 
psychiatric wards by using comprehensive laboratory methods (papers I and II) 
2) To identify the rates of substance-related admissions, as measured by both physicians 
and patients, and to assess the rate of self-perceived need for substance-related 
treatment (paper II).  
3) To study associations between laboratory verified substance intake and 
sociodemographic variables, clinical characteristics and patient self-report (paper II) 
4) To compare physician assessment of recent substance intake with laboratory drug 
analyses (paper III) 
5) To compare on-site urine testing with laboratory drug analyses (paper III) 
6) To estimate the rate of drug influence as assessed by physicians and blood drug 
concentrations (paper I and IV) 
7) To investigate the relationship between drug influence as assessed by physicians and 
blood drug concentrations (paper IV) 
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3. Material 
3.1. Setting 
The study was conducted in a 27-bed acute psychiatric ward at Lovisenberg Diakonale 
Hospital, Oslo, Norway and in an 18-bed acute psychiatric ward in Sørlandet Hospital, 
Arendal, Norway. Both are public hospitals and serve approximately 100.000 inhabitants 
each. From Lovisenberg, patients were also recruited among acute medical admissions, as a 
comparison group in paper I (Table 3).   

3.2.  Study samples  
All papers comprise data collected among acute, consecutive admissions. Paper I consists of 
data collected in a pilot project at Lovisenberg Diakonale Hospital in 2003 (Table 3). Of 116 
acute psychiatric admissions, 100 (86%) were included in the study and 16 (14%) were 
excluded due to lack of biological specimens for drug analysis. Of 253 eligible medical 
admissions, 118 (47%) were randomly selected and informed about the study. Of these, 106 
(90%) were included and 12 (10%) declined.   
Papers II-IV comprise data collected in the main study during 2006 and 2007. At 
Lovisenberg, 309 (88%) of 351 psychiatric admissions were included, 33 (9%) declined, and 
8 (2%) were excluded due to dementia. In Arendal, 47 (42%) of 111 acute admissions were 
included, 50 (45%) declined, 8 (7%) were excluded due to dementia and 6 (5%) were not 
asked to participate. Numbers included in the different papers are shown in Table 3.  
Table 3 Number of admissions included in the study and in the different papers (N).  
Setting 
Consecutive
admissions 
in the study 
period 
Included 
in study  
(%) 
Paper I Paper II Paper III Paper IV 
Pilot study Lovisenberg 2003       
    Psychiatric admissions 116 100 (86%) 100    
    Medical admissions   258 106 (41%) 106    
Main study 2006-2007       
    Lovisenberg psychiatric admissions     351 309 (88%)  298 284 236 
    Arendal psychiatric admissions 111 47 (42%)   41 35 
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Thus, a total of 456 (79%) of 578 consecutive psychiatric admissions were included in the 
study. Overall, the mean age of included patients was 39 years (SD 15) and 47% were males. 
Sociodemographic variables, hospital stay characteristics and discharge diagnoses for the 
patients included in the main study from Lovisenberg and Arendal are given in Table 4. For 
comparison, we have also included data from a national survey of patients admitted to acute 
psychiatric wards (n = 3572) conducted at 19 acute psychiatric wards in 2005 (16). These 
figures will be further discussed in paragraph 6.1.1. 
In this study, some patients with readmissions were included more than once, but we will 
mostly study each admission per se, as also seen in other studies (16, 76). 
 
3.3.  Inclusion and exclusion criteria  
For the main study (papers II-IV), consecutively admitted patients who were willing to 
participate in the study provided written informed consent. If patients were readmitted in the 
project period, they were asked to participate again. Additional inclusion criteria were applied 
for the different papers, according to their specific aims, and these criteria were based on the 
type and time of biological sampling (as described in the papers). Exclusion criteria were 
dementia or mental retardation, as diagnosed by the ward psychiatrist.  
For the pilot study (paper I), patients admitted to the medical ward aged 18-67 who were 
willing to participate in the study provided written informed consent. Exclusion criteria were 
dementia or mental retardation or acute intoxication. For the psychiatric admissions, informed 
consent was not obtained (see ethical considerations, chapter 4.6).  
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Table 4 Sociodemographic and clinical variables for included admissions at Lovisenberg (n = 309) as compared 
to Arendal (n = 47) and a national sample (n = 3572) (16, 17). 
 LovisenbergN = 309
Arendal
N = 47
National sample 
N = 3572 P - value
Age, mean (SD) 39 (14 ) 38 (13) 41 (16) -a
Men 47% 51% 50% 0.538
Non - Norwegian origin 20% 0% 10% <0.001
Living alone 69% 62% 52% <0.001
Homeless 10% 4% 4% <0.001
Care for children 8% 21% 12% 0.022
Married  7% 19%   17% <0.001
Employed 12% 2% 13% 0.088
On welfare  12% 6% 9% 0.180
Disability pension 39% 60% 38% 0.010
Any psychiatric admission previous year 55% 70%  57% 0.146
  
Referral from general practitioner 5% 17% 21% 
<0.001
    Emergency department (”legevakt”) 23% 46% 38% 
    Psychiatric emergency department 27% 0% 2% 
    Outpatient clinics 26% 15% 9% 
    Somatic clinics (inpatient or outpatient) 11% 6% 8% 
    Prison  1% 0% 1% 
Admitted at day-time (7-16) 51% 57% 47% 0.538
Followed by police  15% 4%  25% <0.001
In voluntary admission 57% 28%  42% <0.001
Suicidal plans or self-harm at admission 33% 21%  27% 0.068
Use of belts 7% 0%  4% 0.022
Seclusion 21% 9% 20% 0.130
Transfer to long-term inpatient care 17% 34% 15% 0.001
Admission GAF-F, mean (SD) 36 (11) 40 (9) 37 (-)a -a
Admission GAF-S, mean (SD) 35 (12) 38 (11) 35 (-)a -a
Discharge GAF-F, mean (SD) 45 (12) 47 (11) 45 (-)a -a
Discharge GAF-S, mean (SD) 49 (11) 49 (10) 47 (-)a -a
Length of stay in days 9.2 (11.7) 4.5 (11.9) 9.5 (12.5) -a
  
Main discharge diagnoses (ICD-10)  
    F1 Substance use disorders 29% 21%   7% <0.001
    F2 Schizophrenia 22% 19%  24% 0.606
    F3 Affective disorders 25% 32%  29% 0.279
    F4 Neurotic disorders 8% 13%   10% 0.360
    F6 Personality disorders 10% 11%  8% 0.294
Any drug use disorder (F1) 45% 36%  22% <0.001
GAF; Global Assessment of Functioning. The Lovisenberg data are studied in paper II, in relation to findings of 
psychoactive substances (298 admissions with biological samples for drug analyses). Values < 0.002 remain 
significant with Bonferroni correction.                                                                                                                       
a Not computable because of incomplete data from the national sample                                                                                                
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4. Methods
4.1. Measurements 
4.1.1. Laboratory analyses 
Blood and urine samples were collected as soon as possible after admission. Samples of 
whole blood for drug analyses were collected by laboratory staff using 5 mL Vacutainer® 
tubes containing fluoride and heparin (BD Diagnostics, Franklin Lakes, NJ, USA). Additional 
blood for routine laboratory analyses was obtained simultaneously. Urine samples were 
collected with 200 mL vacuum containers, which were distributed by ward staff, and patients 
were not observed while sampling. To ensure anonymity, all samples were given a unique 
project number in a research protocol. The samples were refrigerated as soon as possible and 
brought on a weekly basis to the Division of Forensic Toxicology and Drug Abuse, 
Norwegian Institute of Public Health. In a biobank established for the project, samples of 
blood and urine were then frozen at about -20°C within a few days after arrival. Finally, 
within a few weeks, samples were analyzed for drugs by using routine toxicological methods. 
Using the enzyme multiplied immunoassay technique (EMIT® II  Plus Assay, Microgenics, 
USA), all urine samples were screened for a wide range of substances and their metabolites, 
as shown in Table 5. Blood samples were screened with EMIT for opiates, amphetamines, 
cocaine and cannabis (151), and by high-performance liquid chromatography-mass 
spectrometry (LC-MS) for other drugs (152). Blood samples were screened for alcohol with 
an enzymatic dehydrogenase method, as were the urine samples of patients who did not 
provide blood (153). All positive screening results in urine and blood were confirmed by GC-
MS or LC-MS (154-156). A headspace gas chromatographic flame ionization detection (HS-
GC-FID) method was used for ethanol determination in blood (157). Cut-off values are 
presented in Table 5. Urine samples were also analyzed for creatinine and pH. The laboratory 
had been accreditated since 1996 according to ISO 17025 for performing these confirmation 
and quantification methods for forensic toxicology purposes by the Norwegian body for 
accreditation of laboratories (Norsk Akkreditering, Kjeller, Norway).  
Substances were reported as present if they were detected in urine or blood, except in the 
cases of benzodiazepines or opiates that had been administered after admission but before 
sampling. The laboratory results were only used for research purposes and were available for 
the researchers some weeks after admittance. In papers I-III both blood and urine drug results 
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were used, in paper IV only blood analyses were used. In paper I, we described a method to 
estimate the degree of drug influence, which is based on blood drug concentrations.  
For a subsample of included patients, oral fluid (N = 98) and hair samples (N = 30) were also 
collected for drug analyses. These results will not be described in this thesis, but the samples 
of oral fluid have been included in a separate paper (158). 
 
Table 5 Substances included in the study with analytic methods and cut-off values (ng/ml) for screening and 
confirmation in blood and urinea  
 Bloodb Urineb 
 Screening Confirmation Screening Confirmation 
Substance  Method Cut-off Method Cut-off Method Cut-off Method Cut-off 
Benzodiazepines - - - - EMIT 200 - - 
    Diazepam  LC-MS 57 LC-MS 57 - - LC-MS 150 
    Oxazepam LC-MS 287 LC-MS 287 - - LC-MS 144 
    Flunitrazepam LC-MS 2 LC-MS 2 - - LC-MS 28 
    Clonazepam         LC-MS 9 LC-MS 9 - - LC-MS 32 
    Nitrazepam         LC-MS 14 LC-MS 14 - - LC-MS 25 
    Alprazolam LC-MS 9 LC-MS 9 - - LC-MS 31 
Zopiclone LC-MS 19 LC-MS 19 - - - - 
Opiates EMIT 85 - - EMIT 300 - - 
    Morphine         - - GC-MS 15 - - LC-MS 29 
    Codeine         - - GC-MS 32 - - LC-MS 60 
Methadone LC-MS 62 LC-MS 62 EMIT 300 LC-MS 62 
Dextropropoxyfen LC-MS 68 LC-MS 68 EMIT 300 LC-MS 200 
Buprenorphine - - - - EMIT 5 LC-MS 4 
Barbituratesc     LC-MS 4640 LC-MS 4640 EMIT 200 - - 
Alcohold         ADH 0.002 HS-GC-FID 0.004 ADH 0.01 HS-GC-FID 0.01 
Amphetamines         EMIT 54 - - EMIT 300 - - 
    Amphetamine - - GC-MS 41 - - LC-MS 135 
    Methamphetamine - - GC-MS 45 - - LC-MS 150 
    Ecstasy - - GC-MS 58 - - LC-MS 77 
Cannabis EMIT 9 GC-MS 1 EMIT 20 LC-MS 10 
Cocaine         EMIT 91 GC-MS 60 EMIT 300 LC-MS 60 
LC-MS indicates liquid chromatography-mass spectrometry; GC-MS, gas chromatography-mass spectrometry; 
EMIT, enzyme multiplied immunoassay technique; ADH, alcohol dehydrogenase method for alcohol; HS-GC-
FID, Headspace gas chromatographic flame ionisations detection.   
a Due to conversion from molar units, some of the numbers in the table may seem odd. Blood concentrations are 
given and plasma/blood concentration ratios for some drugs are markedly above 1. Cut-off values are given for 
analyses performed in 2006-7 (papers II-IV). Values for blood analyses performed in 2003 are given in paper I.  
b Analyses in blood and urine also included lorazepam, ethylmorphine, isopropanol, methanol and 6-
monoacetylmorphine (6-MAM, a metabolite of heroine), and, in blood; carbamazepine, meprobamate, 
carisoprodol, phenazepam, midazolam, zolpidem, and, in urine; pholcodin, phencyclidine, lysergic acid 
diethylamide (LSD) and 2-ethylidene-1.5-dimethyl-3.3-diphenylpyrrolidine (EDDP, a metabolite of methadone). 
Urine gammahydroksybutyrat (GHB) was analyzed only on special request and urine creatinine and pH were 
analyzed for all samples.  
c Phenobarbital.    
d Values given in %. 
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4.1.2. On-site urine testing 
In paper III, we used data from the routine performance of “Clearview 6 panel Drug Screen 
Card” (Inverness Medical International, Bedford, UK). This specific device was chosen 
because it was routinely used at the Lovisenberg ward at the time of the project. Cut-off 
values are presented in the paper. Results of the on-site test were routinely documented in 
case notes.  
 
4.1.3. Physician assessment 
Data from the physician assessment described here were used in papers II-IV. At admission, 
all patients underwent a routine clinical interview by the physician on call. Subsequently, the 
physician completed a study form including the following four questions (see Appendix):  
Based on all available data at the time of assessment:  
1) During the last week and at the time of assessment; to which extent has the patient had 
positive symptoms? (The positive subscore of the positive and negative syndrome scale, 
PANSS: Delusions, conceptual disorganization, hallucinatory behaviour, 
hyperactivity/agitation, grandiosity, suspiciousness and hostility, as assessed on a scale from 
0-7, with increasing severity) (159) (papers II and IV) 
2) Is there any information on recent substance intake (tick off): Benzodiazepines, opiates, 
amphetamines, cannabis, cocaine, alcohol, others or none? (paper III) 
3) In your opinion, is this patient under drug influence at admission: Not at all, mildly, 
moderately, markedly or uncertain? (paper IV) 
4) Do you think that the current admission was related to substance use: Not at all, partly or 
totally? (paper II)  
The assessment was meant to be overall judgments by the physician on call, based on all 
available information from patients, companions, clinical manifestations, referring physician 
and routine laboratory analyses. Questions 2 and 3 were derived from the Clinical Test for 
Impairment (131).  

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4.1.4. Patient self-report  
In paper II, we used data obtained by a patient self-report questionnaire which was obtained in 
230 (77%) of the 298 admissions and included a question on tobacco use, the Hopkins 
Symptom Checklist 10-item version (HSCL-10) (160) and the questions “Do you think that 
the current admission was related to substance use?”, “Do you think you need professional 
help to change your alcohol use?” and “Do you think you need professional help to change 
your drug use (tick off): Not at all, partly or totally? (see appendix). The latter question is part 
of the Drug Use Disorders Identification Test-Extended (DUDIT-E), which includes both 
medicinal and illegal drug use (161). The self-reports also included the 10-item Alcohol Use 
Disorder Identification Test (AUDIT) (99), the 11-item Drug Use Disorder Identification Test 
(DUDIT) (162) and the 2-item Lie/Bet Questionnaire for screening for pathological gamblers 
(163). The results of the self-report questionnaires were documented in medical records and 
were available for the clinicians. The results of the Lie/Bet Questionnaires are not presented 
in this thesis.  
 
4.1.5. Review of medical records and clinical diagnoses  
For papers II-IV, sociodemographic and clinical characteristics for the included patients were 
obtained by review of medical records and are shown in Table 4. The review was performed 
by the first author for all patients at Lovisenberg and by research assistants in Arendal. Most 
variables were gathered and coded with similar methods as in the national survey performed 
in 2005 (16), including the Global assessment of functioning and symptoms (GAF, split 
version) (164, 165) and an assessment of suicidal risk at admission by rating patients on a 
scale from 1 to 6, where 1 = ‘no risk’ and 6 = ‘recent severe self-harm with obvious intention 
to die’ (121). The researchers also obtained additional information about prescribed 
medication before and during hospitalization. On this basis, we could exclude laboratory 
findings that could only be explained by substances prescribed after admission (papers II-IV), 
and we could estimate the rate of nonprescribed use of medicinal drugs before admission 
(paper II).   
Clinical diagnoses were also obtained from medical records. These diagnoses were routinely 
stated at discharge and always controlled by a ward psychiatrist. During the hospital stay, 
most patients at Lovisenberg (66%) were interviewed with the Norwegian 16-item version of 
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the Mini-International Neuropsychiatric Interview (MINI) (96) and the 7-item Iowa 
Personality Disorder Screen (166). These results were documented in medical records and 
were available for the clinician performing the diagnostic assessment at discharge. The use of 
MINI has been described in a separate paper (101).    

4.2. Ethical considerations 
The study was approved by The Regional Committee for Medical Research Ethics and the 
Norwegian Data Inspectorate. Blood sampling did not result in any dangerous episodes, and 
laboratory results were only used for research purposes. The results of patient self-report and 
of the MINI interviews were documented in medical records, with the consent of the patients. 
This information was available for the clinicians and could therefore possibly have influenced 
treatment and referral strategies. For example, a MINI interview revealed previous hypomanic 
episodes for a patient with the clinical diagnosis of recurrent depression, and this information 
altered treatment strategies.    
In the main study, patients were given written and oral information about the study during the 
first days of their admission. If the patient understood the nature of the research and was 
willing to participate, he or she was asked to sign a consent form (see appendix). If patients 
were unable to give informed consent during the first days, they were approached again when 
their mental state improved. Blood and urine samples were sent for drug analyses only if the 
patient wanted to participate in the study. When samples were collected from patients who did 
not want to participate in the study, these were destroyed. Included samples were only 
analyzed with regard to psychoactive substances, and they were destroyed by the end of the 
project period.  
For data collected in 2003, medical patients were given written and oral information about the 
study as part of the initial assessments. If the patient understood the nature of the research and 
was willing to participate, they were asked to sign a consent form. For the psychiatric 
patients, informed consent was not asked for or obtained. We argued that many patients 
would be severely ill at the time of admission, and that it would not be possible to obtain 
consent before sampling. With this exception, the study was conducted in accordance with the 
declaration of Helsinki (167). Other recent studies have also been performed without 
informed consent of the patients (80, 90), and some previous studies performed drug analyses 
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under the guise of other somatic tests (143, 148). We experienced in the main project that 
informed consent very well can be obtained, within a few days after admission, and we 
recommend future studies to do so.   
 
4.3. Statistical analyses 
The Statistical Package for the Social Sciences versions 12 – 16 were used for all statistical 
analyses (SPSS, Chicago, USA). A list of variables included in the different papers is shown 
in Table 6. Count data were presented as numbers (%). Continuous data with approximate 
normal distributions were presented as means (SD) and non-normal data as medians (range). 
For comparison of two groups, a chi square test was used for dichotomous dependent 
variables, and Student’s t-test or Mann Whitney U-test for continuous dependent variables. 
All tests were two-tailed and we used a significance level of 0.05. For comparison of multiple 
groups, 2 tests were used for dichotomous dependent variables and post-hoc pairwise 
comparisons between all subgroups were Bonferroni corrected (paper II). Group differences 
between multiple groups in normally distributed continuous variables were analyzed with 
one-way analysis of variance (ANOVA), and post-hoc comparisons were performed using the 
Tukey HSD test. Kruskall-Wallis tests were used for non-normal data with Mann-Whitney 
tests and Bonferroni corrections for post-hoc pairwise comparisons. Also, the physician’s 
ability to detect recent substance intake was characterized by sensitivity and specificity (paper 
III). To investigate the impact of various factors on the clinical assessment of drug influence, 
we used a binary logistic regression model generating odds ratios (OR) with 95% confidence 
intervals (95% CI) (paper IV). For further details on the statistical analyses, the reader is 
referred to each paper.   
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Table 6 List of variables included in Papers I-IV 
Variables Paper I Paper II Paper III Paper IV 
Age (X)a X X X 
Gender (X)a X X X 
Education etc  X   
Involuntary admission  X X X 
Suicidal risk score  X   
Length of stay in days (X)a X X X 
Discharge diagnoses (ICD-10) (X)a X X X 
Physician on call      
    Psychotic symptoms   X  X 
    Global assessment of functioning  X   
    Admission related to substance use  X   
    Recent drug intake   X X 
    Drug influence    X 
Patient self-report      
    Hopkins symptom checklist-10  X   
    Use of tobacco  X   
    Admission related to substance use  X   
    Perceived treatment need  X   
Laboratory data     
    Blood X X X X 
        Calculation of blood drug concentration scores X   X 
    Urine X X X  
        On-site tests   X  
ICD-10; International Classification of Diseases.                                                                                                       
a Obtained on group-level for psychiatric patients, on individual level for medical patients. 
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5. Results  
5.1. Summary of the results 
This chapter presents findings in line with the seven research aims: 
Aim 1: To identify rates of recent substance intake among patients admitted to acute 
psychiatric wards by using comprehensive laboratory methods. 
In a pilot study in 2003, urine and blood samples were collected from 100 psychiatric 
admissions at Lovisenberg Diakonale Hospital (paper I). With chromatographic methods, 
psychoactive substances were found in 63% (95% CI 54%-73%) of the admissions; medicinal 
drugs in 47% (37%-57%), alcohol in 8% (3%-13%) and illegal drugs in 36% (18%-26%). At 
the same ward, in 2006/2007, the same methods were applied among another 298 acute 
psychiatric admissions (paper II). Psychoactive substances were detected in 63% (57%-68%) 
of the admissions, medicinal drugs in 46% (41%-52%), alcohol in 12% (9%-16%) and illegal 
drugs in 28% (23%-33%). A total of 20 different substances were detected, with up to ten in a 
single patient.  In both studies, amphetamines were particularly commonly detected; 22% 
(14%-30%) and 16% (12%-20%). The laboratory findings are summarized in Table 7, which 
also includes the figures from Arendal and separate figures for blood and urine (see additional 
results, chapter 5.2). As compared with most previous studies, these detection rates are high 
and may partly be explained by the use of comprehensive laboratory methods  
    
Aim 2: To identify the rates of substance-related admissions, as measured by both physicians 
and patients, and to assess the rate of self-perceived need for substance-related treatment.  
At 298 psychiatric admissions in 2006/2007, both patients and physicians were asked if they 
thought that the admission was related to substance use, and patients were also asked if they 
needed professional help for substance use (paper II). Substance use was seen as being related 
to the admission by 42% (36%-48%) of patients and 45% (39%-51%) of physicians on call, 
and a need for professional help for substance use was reported by one-third of patients. Also 
by using non-laboratory methods, these results confirm the major impact of recent substance 
use in acute psychiatric wards, and demonstrate that many patients want professional help to 
change their substance use behaviour. 
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Aim 3: To study associations between laboratory verified substance intake and 
sociodemographic variables, clinical characteristics and patient self-report. 
Urine and blood samples were collected from 298 psychiatric admissions and extensively 
analyzed for medicinal drugs, alcohol and illegal drugs (paper II). Sociodemographic and 
clinical variables were obtained by a review of medical records. Psychotic symptoms at the 
time of admission were assessed by the physician on call using the positive subscale of the 
Positive and Negative Syndrome Scale (PANSS). Patients with negative tests and with 
medicinal drugs only did not differ significantly from the other groups on any variable in the 
post-hoc analyses. Patients using alcohol had a high suicidal risk score at admission and the 
shortest length of stay (median one day). Use of illicit drugs was associated with psychotic 
symptoms and readmission. Given the high rates of substance use and the important clinical 
associations, drug screening seems warranted in acute psychiatric settings. Interventions 
designed for substance-using patients should be developed and integrated.    
 
Aim 4: To compare physician assessment of recent substance intake with laboratory drug 
analyses. 
The sample comprised 325 consecutive admissions from two acute psychiatric wards (paper 
III). Physicians on call were asked to judge if the patient had recently taken benzodiazepines, 
opiates, alcohol, amphetamines, cannabis or cocaine. Blood and urine samples were obtained 
and analyzed with chromatographic laboratory methods for a wide range of substances. 
Physicians’ assessments were compared with the reference standard of laboratory analyses. 
The sensitivity of the physician’s assessment was highest for amphetamines (76%) (95%CI 
64%-88%), followed by benzodiazepines (61%) (53%-68%), opiates (57%) (37%-75%), 
cannabis (55%) (42%-68%) and cocaine (50%) (10%-90%), whereas specificity was above 
90% for all substances. The study indicates clinical under-detection of recent substance intake 
among acute psychiatric admissions.  
 
Aim 5: To compare on-site urine testing with laboratory drug analyses. 
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Of 325 included admissions, a routine on-site urine screening test was performed in 92 (paper 
III). The results of the on-site urine tests were compared with the reference standard of 
laboratory urine analyses. The sensitivity of the on-site test ranged from 76% (58%-94%) for 
amphetamine to 97% (91%-100%) for cannabis, and specificity ranged from 82% (72%-92%) 
for cannabis to 100% (100%) for cocaine. On-site urine testing identified substance use that 
was not recognized by the physician’s initial assessment, although specificity for cannabis and 
benzodiazepines was low. Chromatographic methods, which offered important supplementary 
information about substance use, should be considered for the routine screening of acutely 
admitted psychiatric patients. 
 
Aim 6: To estimate the rate of drug influence as assessed by physicians and blood drug 
concentrations. 
In 2003, 100 psychiatric admissions were included (paper I). On the basis of blood drug 
concentrations, drug influence was estimated in 26% (18%-26%) of admissions. From the 
data collection in 2006/2007, 271 acute admissions were included (paper IV). At admission, 
the physician on call performed an overall judgment of drug influence. Psychotic symptoms 
were assessed with the positive subscale of the Positive and Negative Syndrome Scale. 
Quantitative results from blood analyses were used to calculate blood drug concentration 
scores. Patients were judged as being under the influence of drugs and/or alcohol in 28% 
(95% CI 23%-34%) of the 271 admissions. Markedly elevated blood drug concentration 
scores were estimated for 15% (11%-20%) of patients. These findings demonstrate that many 
are under the influence of drugs or alcohol at the time of admission. 
 
Aim 7: To investigate the relationship between drug influence as assessed by physicians and 
blood drug concentrations. 
Among 271 admissions, physician assessment showed a moderate positive relationship to the 
blood drug concentration scores (r = 0.52, p < 0.001) and related also independently to 
symptoms of hyperactivity/agitation and to the detection of alcohol, cannabis and 
amphetamines (paper IV).  
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5.2. Additional results 
The illustrations below were not published in the papers, but are included here because of 
their relevance for the thesis. In a summary of laboratory findings from the two data 
collection periods at Lovisenberg and the one in Arendal, there were no significant 
differences (Table 7). Because the sample size in Arendal was small, the confidence intervals 
were wide.  
Paper II was based on the laboratory findings in blood and/or urine from the second data 
collection period in Lovisenberg (N = 298). Detection of more than one drug was common, 
and the overlap of different drug groups can be illustrated by a Venn diagram (Figure 1). 
When comparing specific detection rates in blood and urine, no significant differences were 
found, with the exception of morphine that was more commonly detected in urine (Table 7). 
When comparing findings in blood and/or urine with physician assessment, laboratory rates 
were higher for benzodiazepines and lower for alcohol.  
Detection rates from paper II were further stratified on age and gender (Table 8). Nitrazepam 
was more commonly detected among women (17% vs. 5%, p < 0.01) and amphetamines 
among men (25% vs. 8%, p < 0.001), and benzodiazepines (diazepam) were most common in 
the highest age group and illegal drugs (cannabis) were most common in the lowest age group 
(p < 0.01 for all). Illegal drugs were detected among 38 (59%) of 64 men in the lowest age 
group; 36% were positive for amphetamines and 38% for cannabis.  
The moderate positive relationship between physician assessment and blood drug 
concentration scores described in paper IV can also be illustrated by a column chart (Figure 
2). In this chart there were five blood drug concentration groups; low concentrations (1 point), 
mildly elevated (2-3 points), moderately elevated (4-5) and markedly elevated (6 and above). 
In the paper, we merged the two first groups into “moderately elevated” and the two latter into 
“markedly elevated”.  
 

41
Table 7 Summary of laboratory findings in blood and/or urine among patients studied in Arendal in 2007 and in 
Lovisenberg in 2003 and 2006-7. From the latter data collection, separate results are also shown for blood, urine 
and physician assessment. Values are given in % (95% CI). 
 
Arendal 
2007 
Blood 
and/or 
urine 
N = 43 
Lovisenberg 
2003 
Blood 
and/or 
urine 
N = 100 
Lovisenberg 
2006-2007 
Blood 
and/or 
urine 
N = 298 
Lovisenberg  
2006-2007  
 
Blood 
N = 287
 
Urine 
N = 257 
Physician 
assessment 
N = 295
Any drug 74 (61-87) 63 (54-73) 63 (57-68) 58 (53-64) 58 (52-64) 61 (56-67)
 3 drugs 23 (11-36) 19 (11-27) 17 (13-21) 11 (8-15) 19 (14-24) -a
Medicinal drugs 61 (46-73) 47 (37-57) 46 (41-52) 40 (34-45) 40 (34-46) 33 (28-39)
    Benzodiazepines  58 (43-73) 40 (30-50) 43 (38-49) 32 (27-38) 37 (31-42) 29 (24-34)
        Diazepam or met 54 (39-68) 34 (25-43) 34 (29-39) 24 (19-29) 31 (25-36) -a
        Flunitrazepam 5 (0-11) 5 (1-9) 6 (4-9) 4 (1-6) 5 (3-8) -a
        Clonazepam 9 (1-18) 10 (4-16) 11 (8-15) 8 (5-11) 9 (5-12)  -a
        Nitrazepam 9 (1-18) 5 (1-9) 11 (8-15) 9 (6-13) 9 (5-12) -a
    Opiates  7 (0-15) 8 (3-13)  9 (6-12) 4 (2-7) 11 (7-14) 9 (6-12)
        Morphine 7 (0-15) 7 (2-12) 8 (5-11) 3 (1-5) 10 (7-14) -a
        Codein 5 (0-11) 5 (1-9) 5 (3-8) 4 (2-6) 7 (4-11) -a
    Opioids 7 (0-15) 9 (4-15) 4 (2-6) 4 (2-6) 4 (2-6) -a
        Methadone 2 (0-7) 9 (4-15) 3 (1-5) 4 (2-6) 3 (1-5) -a
Alcohol 14 (4-24) 8 (3-13) 12 (9-16) 12 (8-16) 18 (4-41)b 26 (21-31)
Illegal drugs 30 (17-44) 36 (27-45) 28 (23-33) 21 (16-26) 28 (23-34) 22 (18-27)
    Amphetamines 21 (9-33) 22 (14-30) 16 (12-20) 11 (7-14) 16 (11-20) 14 (11-19)
    Cannabis 23 (11-36) 17 (10-24) 18 (14-23) 12 (8-16) 20 (15-25) 12 (9-16)
    Cocaine 0 (0) 2 (0-5) 2 (0-4) 1 (0-2) 2 (0-4) 2 (0-3)
a These variables were not assessed by the physicians.                                                                                               
b Alcohol in urine was detected in 2 of 11 patients where blood samples were not obtained.  
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Table 8Laboratory findings in blood and/or urine among 298 patients studied in Lovisenberg in 2006-7, 
according to age and gender. Values are given in % (95% CI).
Gender Age groups 
Men 
N = 138 
Women 
N = 160 
18-34 years 
N = 148 
35-50 years 
N = 87 
51-80 years 
N = 63 
Any drug 66 (58-74) 60 (52-68) 61 (53-69) 59 (48-69) 73 (62-84)
 3 drugs 20 (13-26) 16 (10-21) 18 (11-24) 20 (11-28) 14 (6-23)
Medicinal drugs 43 (35-51) 49 (42-57) 39 (31-47) 46 (36-56) 64 (52-75)c
    Benzodiazepines  38 (30-46) 48 (40-56) 37 (29-44) 40 (30-51) 64 (52-75)b
        Diazepam or met 29 (21-36) 38 (31-46) 27 (20-34) 32 (22-42) 52 (40-65)b
        Flunitrazepam 7 (3-12) 6 (2-9) 7 (3-11) 7 (2-12) 5 (0-10)
        Clonazepam 12 (7-18) 10 (5-15) 12 (6-17) 14 (7-21) 6 (0-12)
        Nitrazepam 5 (1-9) 17 (11-23)b 9 (4-13) 12 (5-18) 18 (8-17)
    Opiates  11 (6-16) 7 (3-11) 6 (2-10) 14 (7-21) 8 (1-15)
        Morphine 10 (5-15) 6 (3-10) 6 (2-10) 13 (6-20)  6 (0-12)
        Codein 7 (3-12) 4 (1-7) 2 (0-4) 9 (3-15) 8 (1-15)
    Opioids 4 (1-8) 4 (1-8) 4 (1-7) 7 (2-12) 2 (0-5)
        Methadone 4 (1-7) 3 (0-6) 3 (0-5) 7 (2-12) 0 (0)
Alcohol 12 (7-18) 13 (7-18) 11 (6-16) 13 (6-20) 16 (7-25)
Illegal drugs 40 (32-48) 18 (12-24)a 38 (30-46) 20 (11-28) 18 (8-27)b
    Amphetamines 25 (18-33) 8 (3-12)a 20 (14-27) 13 (6-20) 10 (2-17)
    Cannabis 23 (16-30) 14 (9-20) 26 (19-33) 12 (5-18) 10 (2-17)b
    Cocaine 2 (0-5) 2 (0-4) 4 (1-7) 0 (0) 0 (0)
a p < 0.001, b p < 0.01, c p < 0.05. 

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31
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Legal drugs 
N = 138 (46%)  
Alcohol
N = 37 (12%) 
Illegal drugs 
N = 84 (28%)     
 
Figure 1 Laboratory findings as illustrated by a Venn diagram. Legal drugs, alcohol or illegal drugs were 
detected among 187 (63%) of 298 psychiatric admissions.  Values are given in n (%). 

44
  
 
 
Figure 2 The percentage of patients being clinically judged as influenced by drugs, as related to blood drug 
concentrations. The total numbers of patients in each group are indicated at the bottom of each column. The 
differences between the groups are shown above the columns (total N = 271).  
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6. Discussion 
6.1. Methodological considerations  
6.1.1. Study design 
We used a cross-sectional design to determine the rates of substance use and to compare 
clinical assessment and laboratory findings. A cross-sectional design does not enable 
conclusions about cause and effect. However, this type of observational study is well suited 
and commonly used to identify prevalence, risk factors for disease, and to evaluate diagnostic 
procedures. The method provides a description of the population only at the time when 
information is collected. At Lovisenberg, data was collected both in 2003 and 2006, which 
enables a study of possible changes in substance use patterns over time.  
The following limitations of the study design should also be acknowledged. First, paper I was 
limited by the lack of informed consent and individual data on sociodemographic and clinical 
characteristics. Second, our definition of nonprescribed use of medicinal drugs may be 
questioned, and we could rather have included validated instruments such as the 
Benzodiazepine Dependence Questionnaire (168). Third, alcohol is rapidly removed from the 
body, and additional biomarkers with longer detection times, such as ethyl glucoronide (169) 
or carbohydrate deficient transferrin (116), could have added valuable information and 
increased the estimates of recent alcohol users. Fourth, with regard to the characteristics of the 
participating physicians, we only obtained data on name and gender. Additional information, 
such as on their previous experience, could have been valuable in exploring the relationships 
between physician assessment and laboratory findings. Finally, in paper IV, the physicians 
were not asked to specify which drugs were the probable cause of influence and neither why 
some patients were impossible to evaluate with regard to drug influence. These aspects could 
potentially have given valuable information. In addition, abstinence or withdrawal syndromes 
could have been one of the alternatives, also according to the comments made by some of the 
physicians. 

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6.1.2. Internal validity 
Internal validity is usually discussed with regard to selection bias, information bias and 
statistical validity / confounding. 
Selection bias 
Selection bias refers to errors that may have influenced participation in the study and the 
selection of participants. These errors could cause the results to be non-representative of the 
target population. If the non-participants carry characteristics which are associated with the 
outcome results, selection bias may have occurred. 
In the Lovisenberg sample of 2006-7, 309 (88%) of 351 admissions were included (Table 3). 
We found no difference between those who were included and not, with regard to age, gender, 
substance related diagnoses at discharge and readmissions in the study period (p > 0.2). Non-
participants were, however, more often admitted on an involuntary basis (81% vs. 57%, p = 
0.003) and more often receiving a diagnosis of schizophrenia at discharge (41% vs. 25%, p = 
0.037). We have no reason to believe that the substance use patterns of non-participants 
differed significantly from the participants, and we therefore assume that the overall detection 
rates were representative for patients admitted to this ward.  
In Arendal, we aimed at including 100 admissions, but this did not succeed due to several 
practical obstacles. A total of 47 (42%) of 111 admissions were included, and because of the 
small sample size, these data have only been used in papers III and IV having a 
methodological focus. When comparing participants and non-participants, no difference was 
found with regard to age, gender, involuntary admissions, discharge diagnoses and 
readmissions in the study period (p > 0.2). For the Lovisenberg admissions included in paper 
I, only a limited number of clinical data was obtained at group level, and participants could 
therefore not be compared with non-participants.   
Information bias 
Information bias refers to systematic errors in data collection or analysis. In this thesis, 
misclassification of respondents into either “case” or “not case” is such a possible error. For 
example, in paper II, laboratory results were used as the basis for dividing admissions into 
four groups. Relatively large and heterogeneous groups may increase the risk of losing 
relevant information. Among patients placed in the illegal drug group, for example, possible 

47
differences between the users of cannabis and amphetamines may not have been discovered. 
In addition, the grouping was based on a single laboratory test, which may be insensitive for 
the severity of substance use problems. Furthermore, most patients do not belong to one 
specific drug group over time. The use of cut-off values for ordinal variables (e.g. the clinical 
assessment of drug influence) and continuous variables (e.g. blood drug concentrations and 
AUDIT) also introduces the possibilities of misclassifications. Some other aspects of 
information bias (e.g. reporting bias and recall bias) will be discussed in chapter 6.1.3., with 
regard to physician assessment and patient self-report. 
Statistical validity / confounding 
Although the main sample size is large compared to many other studies, subgroup analyses 
were challenged by small groups. For example, in paper II, there were few admissions in the 
alcohol group, which reduced the statistical power of subgroup analyses and could cause Type 
II errors. The use of confidence intervals reduces the uncertainties in detection rates related to 
sample size and increases the generalization of the results (Tables 7 and 8). Also, the multiple 
testing performed in papers II and IV was Bonferroni corrected, but this method may be too 
conservative (170). 
Confounding occurs when a covariate is associated with both the outcome variable of interest 
and a selected independent variable resulting in an incorrect association. Controlling for 
known confounding factors may be done during analyses by either stratification of the data or 
by multivariate analyses. In this thesis, confounding has been addressed by both these 
methods. In chapter 5.2, detection rates were stratified on age and gender (Table 8), and in 
paper IV, binary logistic regression analyses were performed. However, there may be 
confounders for which we have not controlled because of a lack of appropriate data and small 
sample size. For example, we lack data on previous discharge diagnoses, which is a potential 
confounder when comparing physician assessment and laboratory results.  

6.1.3. Validity and reliability of measurements 
Laboratory analyses 
Both screening and confirmation analyses are required to provide a robust laboratory finding 
of a given substance (30). As opposed to most previous research in the area, this two-step 
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procedure was applied throughout the present study and ensures high reliability and validity. 
The laboratory methods are used in forensic toxicology and the risk of false positive results is 
very low. However, false negative laboratory results could occur with substances having 
concentrations below screening cut-off values. False negative findings could also have 
occurred because of urine tampering (171). Creatinine and pH were, however, within 
recommended ranges for all samples, which indicate that tampering was not common.   
The use of laboratory results as the reference standard of recent drug intake may be 
questionable, due to several reasons. For substances with short half-lives, clinicians may have 
revealed significant use that was not confirmed by analyses – either because the intake had 
occurred some days earlier or because of the test delay of up to 24 hours. On the other hand, 
findings of substances with long half-lives could be due to intake that was not considered 
“recent” by the physician.  
The use of blood drug findings as the basis for estimation of acute drug influence is also 
subject of methodological concerns. The method described in paper I does not take account of 
the facts that blood concentrations related to intake of a given dose of a drug will vary 
between individuals, and for a given blood concentration, the degree to which a drug 
influences behaviour or symptoms will also vary. Also, the calculation of blood drug 
concentration scores (papers I and IV) was based on an assumption of additive effects of 
psychoactive substances (172, 173). Substances may, however, interact in different ways; it 
may be that e.g. sedating benzodiazepines may reduce the chances of observing the drug 
influence effects of more stimulating drugs. Finally, with regard to blood drug concentrations, 
the laboratory has estimated measurement uncertainties of up to +/- 30% (174). However, 
these analytical variations have not been included in the papers, as we did not believe that 
they would bias our findings.  
 
On-site urine testing 
We wanted to evaluate the routine on-site urine testing as performed by clinical staff, but we 
have no data about these persons. Little competence and experience with the test could have 
caused low reliability and validity. Also, the choice of screening device should be based upon 
knowledge of which substances are being abused in the population. In this study, the on-site 
test device was designed to detect ecstasy and cocaine, for which there were a total of 0 and 6 
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confirmed findings, respectively. The device was not designed to detect zopiclone, methadone 
and metamphetamine, for which there were 22, 10 and 50 confirmed findings. Hence, another 
on-site test could have been chosen to have a better match with the observed drug panorama.  
Physician assessment 
The assessment was performed by 39 different physicians. The study questions may have 
been interpreted differently by different persons, and the inter-rater variability was not 
examined or known. To possibly enhance reliability, all physicians had received oral and 
written information about the study form and the project, and a detailed instruction for the 
PANSS positive subscale was attached to the form. Hence, physicians were sensitized to the 
issue of substance use, and reporting bias could have occurred by the physicians over-
reporting both recent intake at admission and substance use disorders at discharge.  
The PANSS was developed to assess psychotic symptoms among patients with schizophrenia 
(159), and there is no published data on the reliability and validity in acute psychiatric 
settings. There are, however, studies using PANSS among acute admissions and among 
patients with bipolar disorders, for example, and serious validity problems have not been 
reported (80, 175). Also, its face validity was good, and in unpublished material from a 
psychiatric intensive care unit, excellent inter-rater reliability was found in assessing 12 
consecutively admitted in-patients (102).  
The question on recent substance intake was ambiguous in at least two ways which could 
reduce its reliability and validity: 1. Medicinal drugs were not mentioned explicitly. 2. Recent 
intake was not defined with regard to time frame.  
1. It was not specified explicitly that the assessment also included medicinal drugs, as it is in 
the Clinical Test for Impairment (131). This may have contributed to the fact that 
benzodiazepines and opiates seldom were ticked off by the physicians. To obtain additional 
data on medicinal drug use, a retrospective review of medical records was performed by the 
researchers. Reviewed documents included the admission case notes and the inpatient 
prescription form, both provided by the physician on call, and all use of medicinal drugs was 
documented. By using this method, many additional users of medicinal drugs were identified. 
The physician assessment of recent intake of medicinal drugs was therefore based on the 
combined results of the study form and the review of medical records. The physician 
assessment of recent intake of alcohol and illegal drugs was based solely on the study form. 
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2. No definition was given on recent intake, and this could therefore be interpreted differently 
by different physicians. However, additional comments were given by most physicians, and 
for only 8 patients, the intake of substances was less recent than one week. For the 
assessments with no details on time and dose of substance intake, there is a risk of including 
an intake that was weeks or months ago. For the assessment of recent substance intake, 
alternative instruments could have been used, and one option is the Time line follow back 
(176). 
Patient self-report 
Acute psychiatric patients may have limited ability for self rating scales due to their 
psychiatric conditions and affected cognitive functions (100). Memory loss could especially 
be a problem for the AUDIT and DUDIT questionnaires in assessing substance use over the 
last year. This recall bias may lead to inaccuracies in the data registered and to 
misclassifications and inaccurate results. However, AUDIT and DUDIT have recently been 
used and validated among persons with severe mental disorders (177). Also, self-report has 
proved a reliable way of assessing tobacco use among acute psychiatric admissions (116). The 
HSCL-10 has demonstrated good sensitivity and specificity as compared with the widely used 
HSCL-25 (178). These questionnaires were however developed for measuring psychological 
distress in the general population, and their psychometric properties among acutely 
hospitalized patients have, to our knowledge, not been studied. Also, few previous studies 
have used self-report questions on substance-related admissions and self-perceived treatment 
needs, and their reliability and validity are therefore not known.  
Review of medical records and clinical diagnoses 
Review of medical records was performed by unblinded researchers, and the information was 
not confirmed or controlled by other persons, which may reduce the reliability and validity of 
this review. Clinical variables such as GAF, suicidal risk and discharge diagnoses were 
obtained. It is known that the routine use of GAF may suffer from low reliability, and group 
consensus has been suggested as a better alternative (179). Clinical diagnoses may also suffer 
from low reliability and validity. During the project period, however, results from self-report 
questionnaires (AUDIT and DUDIT) and structured interviews (MINI and IOWA) were 
documented in medical records for most patients. This could possibly enhance the reliability 
and validity of clinical diagnoses, although we do not know to what degree the clinicians took 
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this information into their diagnostic considerations. A comprehensive diagnostic interview 
such as SCID could have further enhanced the diagnostic validity, but we found that even a 
short diagnostic interview (MINI) was only feasible for two thirds of these patients (101).   
 
6.1.4. External validity 
Generalization of results should always be made with caution, and this applies to our results. 
In order to claim external validity, a study requires internal validity. There are several aspects 
in our methodology, discussed above, which may have resulted in inaccuracies and bias. In 
papers I and II, we identified the detection rates of psychoactive substances among patients 
admitted to the acute psychiatric wards at Lovisenberg. The internal validity of these 
laboratory results is high, and this calls for an evaluation of external validity. For the 
admissions included in paper I, however, only a limited number of clinical data was obtained 
at group level. These data could therefore not be analyzed with regard to representativity.  
For the Lovisenberg admissions recruited in 2006-7 (paper II), we have a number of relevant 
patient background variables. This sample of 309 admissions was compared with data from 
all admissions at Lovisenberg during 2006 (n=1133) (obtained from computerized records), 
and no difference was found with regard to age, gender, involuntary admissions, length of 
stay and discharge diagnoses (p > 0.2 for all). The sample was also compared with included 
admissions in Arendal (n = 47) and data from a national survey of patients admitted to acute 
psychiatric wards (n = 3572) conducted at 19 acute psychiatric wards in 2005 (16). No 
differences were found between the groups for age, gender, GAF – scores, length of stay and 
disorders not related to substance use (p > 0.5) (Table 4). Lovisenberg participants were, 
however, more often of non – Norwegian origin (20% vs. 0% and 10%), homeless (10% vs. 
4% and 4%), unmarried (93% vs. 81% and 83%) and having a substance use disorder as 
discharge diagnosis (45% vs. 36% and 22%) (p < 0.001 for all).  
Some of these differences are also described for the general population. The special position 
of being the largest city and the capital of Norway may lead to an accumulation in Oslo of 
marginalized groups with high levels of substance use and mental symptoms. Substance use is 
more common among young people in Oslo than elsewhere in Norway (180), and many 
psychiatric disorders are more prevalent than in rural areas (181). In Oslo, 18% of the 
population has non-western origin, as compared with 5% in Bergen and Trondheim and only 
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3% in Tromsø (182), but whether this affects the epidemiology of substance use is not known. 
We found that non-western participants commonly had drug-negative urine and blood 
samples (paper II), and it has been shown that substance related disorders are less common 
among patients with non-western origin (183). This indicates that the high proportion of non-
western participants in our sample is likely to minimize the rates of current substance use.   
Acute psychiatric admission practices vary across regions (15), but it is not known whether 
Oslo differs from other Norwegian cities with regard to the pre-hospital treatment of 
psychiatric patients with acute substance use or intoxications, for example in the use of 
psychiatric, medical or substance abuse inpatient facilities. Oslo has a specialized psychiatric 
emergency department, however, from which almost every third Lovisenberg admission was 
referred for admission (Table 4). Psychiatrists can be more reluctant to admit patients than 
less experienced physicians (184), and this may result in a more selected group of severely ill 
patients among acute admissions in Oslo than elsewhere in Norway. In comparing 
Lovisenberg admissions with the national sample, however, no differences were found with 
regard to GAF-scores, use of restraints, length of stay or discharge diagnoses other than 
substance use disorders (Table 4). The national survey represents an important comparison 
group for our sample, although it was conducted one year before our study. Its reliability and 
validity is not known and we did not have access to the specific data obtained in other acute 
wards in cities like Oslo, Bergen and Trondheim. 
In conclusion, the study sample seems representative for patients admitted to the psychiatric 
unit at Lovisenberg, but not representative at a national level with regard to various 
background variables and substance use patterns. Still, we assume that our findings were 
representative for “big city” - hospitals in Norway. Generalizability to foreign cities should be 
made with caution, however, as both substance use patterns, acute psychiatric services and 
inpatient characteristics differ across regions and countries.  
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6.2. Discussion of main results 
The main findings of the present study were presented in chapter 5.3 and will now be 
discussed one by one. First, however, we will return to the case presentation (Box 2). 
Box 2 Case presentation, 2 years later  
 
 
 
 
 
 
 
 
 
 
 
 
  
In December 2006, Joe had his 17th admission to the acute psychiatric ward. Again, he was referred for 
compulsory observation of up to 10 days because of substance use, aggressive behaviour and psychotic symptoms. 
His previous admission was only a few weeks ago, which lasted for 5 days and he had received the discharge 
diagnosis of F.19.5 substance induced psychosis, due to use of multiple substances. His mother and some care-
givers were increasingly worried for Joe and afraid that he was suffering from a severe mental illness. He had not 
been able to follow any voluntary outpatient treatment, which repeatedly had been offered him. He was homeless, 
unemployed, lived on social welfare and both his mental and somatic health had clearly worsened since his first 
admission, two years ago. 
At admission, he was clinically judged as being drug influenced, but he did not co-operate with regard to somatic 
evaluation or laboratory tests. He accepted antipsychotic medication and hypnotics, and after a few days in the 
locked ward he seemed much calmer and free for psychotic symptoms. On the 9th day, however, he had some 
disturbed behaviour and expressed paranoid ideas. A urine sample was obtained, and the on-site test was positive 
for cannabis. It was not clear when this cannabis was taken, and it was decided to prolong the compulsory 
observation for ten more days. During these days, he was closely observed and abstained from drugs, and he was 
functioning quite well.  
On the 20th day after admission, he was offered a voluntary stay for further treatment and help with his 
socioeconomic situation, but he chose to leave the ward against medical advice. He was still homeless, as his 
mother did not want him to live with her because of his threatening behaviour, and again, he was offered outpatient 
treatment on a voluntary basis. After an extensive diagnostic evaluation, he received the diagnosis of F19.5 
substance induced psychosis, due to use of multiple substances.  
During this admission, clinical staff members were discussing several questions, such as: 
• To what extent did Joe actually use substances? How was his motivation to change his drug use patterns?  
• Was this a primary or secondary psychotic disorder? How could these assessments possibly be performed? 
• If his condition really was substance induced: How could we possibly help Joe from now on? 
• Suppose instead he was suffering from a severe mental disorder: Would then the treatment strategies differ?  
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1. High rates of recent substance intake 
We found that almost two-thirds of the sample was positive for at least one psychoactive 
substance, and a total of 20 different substances were detected, with up to ten in a single 
patient. The high detection rates from Lovisenberg in the pilot study of 2003 were replicated 
in the main study three years later. Amphetamines were, for example, detected in about one in 
five admissions in both studies. This indicates a relatively stable substance use pattern in the 
admitted population over a three year period. In the same period, there was a continuous 
overload on the ward capacity with a mean bed occupancy of 130% and above (185), and our 
findings suggest a stable and substantial percentage of substance-related admissions. We also  
found that substances were more commonly detected among acute psychiatric than among 
acute medical admissions (paper I). 
Bearing in mind the geographical differences in acute psychiatric services (6, 15) and 
methodological differences across studies, detection rates of specific substances were 
compared with those of previous studies (paper II). Comparison was also challenged by the 
lack of confidence intervals in previous studies. As compared with most previous studies, the 
present detection rates are high and may partly be explained by the use of comprehensive 
laboratory methods (Table 5). Our study sample is not representative in a national perspective, 
but we assume that our findings are representative for other big city hospitals in Norway. In 
Oslo, high detection rates of amphetamines have also been reported from psychotic inpatients 
previously (142), whereas psychotic outpatients have high rates of self-reported use (51). 
High detection rates of amphetamines and other substances were also observed among the 
admissions in Arendal, and this strengthens the assumption that the Lovisenberg findings are 
not unique in Norway.  
In the papers, we have compared our results with studies from Europe and the USA. Recent 
studies among acute psychiatric admissions in Israel and South Africa report on-site urine 
detection rates of any drug of 17% and 44%, respectively (Table A2) (84, 85). In South 
Africa, “Mandrax” was detected among 5% of the admissions, which is a locally produced 
amphetamine, and illustrates that substance use patterns vary across regions and countries. 
Both studies underline that substance use is common and needs to be taken into consideration. 
In line with previous studies, we found that detection rates were associated with age and 
gender. Illegal drugs were detected among the majority of men aged 18-35 years, and this 
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calls for an increased clinical suspiciousness of illegal drug use when assessing young men in 
an acute psychiatric ward.   
As stated in paper III, use of psychoactive substances is not necessarily of clinical 
significance, and benzodiazepines and opiates are commonly prescribed for therapeutic 
reasons. Still, recent intake of substances may result in severe medical conditions (31) and 
increase the risk of violence and suicide (57, 186). Even small amounts of a drug may pose 
problems for people with mental illness (59). Also, for patients using multiple substances, the 
risk of side effects caused by drug interactions is further increased by the trend toward 
polypharmacy in psychiatric inpatient treatment (44).  
 
2. Every second admission was related to substance use and every third patient reported 
a need for professional help  
It is noteworthy that a similar percentage of physicians and patients saw the admission as 
being related to substance use. In previous studies, patients often tended to deny substance use 
and its negative effects (116, 117). Our finding indicates that patients in this study sample 
were not under-communicating their recent substance use and its relation to the current 
admission.  
It is also an interesting finding that one third of patients reported a need for professional help 
for their substance use. Self-perceived treatment need among patients admitted to acute 
psychiatric wards is not widely evaluated, and our finding suggests that two simple questions 
may rapidly identify patients with problematic substance use and perceived treatment need. 
On the other hand, these questions may also identify patients with a clinically problematic 
substance use and with no perceived treatment need. According to the theories of motivational 
interviewing and the stages of change, these patients may be in a “pre contemplation stage” 
with regard to their substance use, and comprise specific challenges for health care providers 
(187, 188). The questions were a part of the DUDIT-E questionnaire, which includes 66 
questions on substance use patterns, motivation to change and perceived need for professional 
help (161). Such instruments have a potentially high value in providing rapid information of 
relevance for acute psychiatric treatment and referral strategies.  
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In general, lack of motivation for treatment is a common phenomenon among severely 
mentally ill patients seen by emergency psychiatric services. Lack of motivation has been 
associated with danger and paranoid symptoms, and motivational techniques and involuntary 
treatment have been recommended for these patients (189). The evidence for substance 
specific intervention in acute psychiatric settings is limited, however. 
 
3. Recent alcohol intake was associated with suicidal behaviour and short hospital stay, 
and illegal drugs were associated with psychosis and readmission 
The identification of risk factors of substance use can contribute to improved detection 
strategies. Little is known, however, about the sociodemographic and clinical associations of 
toxicological findings among patients admitted to acute psychiatric wards. Our findings 
suggest that acutely admitted patients with both substance use and suicidal behaviour require 
specialized focus (121). The short hospital stays for substance users comprise a major 
challenge for proper assessment and treatment, and underline the importance of the initial 
assessments and the potential for toxicological analyses. Our findings also state that patients 
using illegal drugs constitute a large and marginalized group which calls for clinical concern. 
Amphetamines, which were were detected in one-sixth of patients, are particularly associated 
with serious negative health effects (190), and have a major and increasing impact on 
emergency services (128).  
 
4. Recent substance intake was commonly under detected by the physician on call  
There is a large variation in the asassessment and treatment strategies of acutely admitted 
psychiatric patients. Strategies may depend on local traditions and on available resources, and 
no consensus exists about the most appropriate or cost-effective methods. In this thesis, we 
have compared different methods for assessing recent substance intake. Some of our findings 
on sensitivity, specificity and feasibility are summarized in Table 9. The table also shows the 
approximate costs of these methods and their ability to provide on-site test results and to 
assess the frequency and severity of drug use (i.e. to distinguish between use and abuse).    
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Table 9 Relative comparison of different methods for assessing recent drug intake and drug use 
Method Sensitivity, 
recent intake 
Specificity, 
recent intake 
Feasibility, 
acute ward 
 Cost On-site  
results 
Frequency  
of drug use 
Severity of 
drug use 
Physician’s 
assessment 
+/- +/- +++  0 Yes Yes Yes 
Patient  
questionnaire 
(+/-) (+/-) ++  0 Yes Yes Yes 
Blood GC-MS +++ +++ ++(+)a  +++ No No No 
Urine GC-MS  +++ +++ +(+)  +++ No No No 
Urine on-site +/- +/- +(+)  + Yes No No 
GC-MS, gas chromatography-mass spectroscopy.                                                                                                      
a If performed by trained staff. 
As illustrated in the table, physician’s assessments are feasible, cheap and provide on-site 
results which may include an evaluation of both frequency and severity of drug use. The 
sensitivity and specificity of recent drug intake is moderate, however. We found that many 
substances were under detected by the physician on call; in particular cannabis and 
benzodiazepines. False positive evaluations were also observed.  
The impact of clinical misdiagnosis of recent substance intake among patients admitted to 
acute psychiatric wards is not widely evaluated. Psychoactive substance use is not always 
considered to be of clinical significance, and benzodiazepines and opiates are commonly 
prescribed for therapeutical reasons. Still, unrecognized substance use leads to the risk of 
overlooking severe acute intoxications and withdrawal syndromes (31). Second, even small 
amounts of a drug may pose problems for people with mental illness (59). Third, the 
possibility for adequate intervention and follow-up for patients with problematic substance 
use may be lost.  
 
5. On-site urine testing identified cannabis use that was not recognized by the 
physician’s assessment, although specificity for cannabis and benzodiazepines was low 
The value of on-site urine screening tests among acute psychiatric admissions has not been 
widely evaluated, and although this specific on-site test is widely used, its properties are 
previously unreported. Our findings confirm the shortcomings of on-site urine testing in a 
clinical setting (30, 191) and demonstrate the additional information obtained by 
comprehensive laboratory screening (90, 191) (Table 9).  
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Among patients admitted to acute psychiatric wards, previous studies have contradictory 
findings with regard to the value of toxicological screening. With the use of immunological 
urine methods, some previous studies conclude that routine urine screening is useful (84, 90, 
116), especially among psychotic patients who may be unwilling or unable to provide a 
proper history (66, 70, 117). Another study recommends the use of routine toxicological 
screening as a supplement to structured assessment (72), whereas other studies recommend 
the use of structured interviews rather than routine screening (65, 69, 142). This study 
suggests that chromatographic methods could be considered for routine toxicological 
screening.  
 
6. One-fourth of the patients were under drug influence 
This study is one of the few studies on drug influence among patients admitted to acute 
psychiatric wards (70, 87). It is also the first study presenting detailed results of quantitative 
blood drug analyses in this setting. In paper I, we estimated the degree of drug influence 
(26%) solely based on blood concentrations of various drugs. In paper IV, a similar rate was 
estimated by the physicians on call. We will now return to the case presentation (Box 3).  
Box 3 Case presentation and study findings. 
 
 
 
 
 
 
 
The immediate and feasible collection of blood samples is interesting not only with regard to 
comprehensive drug analyses. Simultaneously, blood was obtained for routine laboratory 
analyses of more than 20 somatic parameters that could potentially provide relevant and 
immediate information for the clinicians (Box 3). In the acute psychiatric wards of 
Joe was admitted five times during the project period, and he consented to study inclusion in all of them.  
• At all admissions, the physicians suspected recent intake of amphetamines and cannabis. Joe was judged as 
markedly impaired at 4 admissions and moderately at one. However, he was not able to give any detailed 
substance use history and he did usually not cooperate with regard to toxicological tests at the time of 
admission. Initial somatic evaluation was performed in two admissions. 
• At only one admission, he cooperated with regard to immediate blood sampling (15 minutes after admission), 
and he was then clinically judged to be under moderate drug influence. Afterwards, he accepted medication with 
antipsychotics and benzodiazepines (olanzapine 20 mg and zopliclone 7.5 mg per os). However, after two hours 
with a gradually less agitated behaviour, he was found unconscious in his bed, with pupillary miosis and intact 
breathing and circulation. He was immediately brought to the acute medical department for further observation. 
He was hypotensive (81/41 mm Hg), and he was given intravenous fluid management. After an hour, he 
awakened and his blood pressure was normalized and he was brought back to the psychiatric ward. The reason 
for this condition remained uncertain, but there were two main differential diagnoses: Either he had intoxicated 
immediately before admission (e.g. opiates), or he had a hypotensive reaction on the medication that he had 
received in the ward.  
• The blood sample was immediately analyzed for somatic parameters, where all results were within normal 
ranges. The sample was later analyzed for the purpose of this study, and the only positive finding was oxazepam 
at a very low concentration (172 ng/ml, whereas a maximum concentration at therapeutic use is 1150). This 
means that he was not under drug influence at the time of admission, and that his condition was probably a 
hypotensive reaction to the medication that he had received in the ward.    
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Lovisenberg and Arendal, blood samples for these analyses are not routinely collected 
immediately after admission, but usually within 1-3 days. In the project period, ward staff 
seemed pleased with having these results available sooner than normal, and, anecdotically, 
there were some examples of low blood sugar and of high C-reactive protein (an indicator of 
acute infection), that resulted in immediate medical interventions. Previous studies among 
psychiatric inpatients have discussed the use of such somatic laboratory analyses (34) and the 
high prevalence of undetected medical disease (31-33). This thesis was not designed to 
evaluate these questions further, but focuses on psychoactive substance use, which is known 
to have a substantial and negative impact on somatic health (48).    
The feasibility of immediate blood sampling among acute psychiatric admissions is 
previously unreported. As compared to urine sampling, blood samples were collected sooner 
and more frequently in both the pilot and the main studies, although some patients did not 
cooperate with regard to sampling at the time of admission (Box 3). This project thereby 
demonstrates that patients can be reluctant or not able to provide urine samples in clinical 
settings. Still, as most substances have longer detection times in urine than in blood (132), 
urine may be the sample of choice for a broader assessment of recent intake. A positive urine 
test, however, does not provide any information on drug influence.  
 
7. Clinical drug influence was positively related to the blood drug concentration scores, 
to symptoms of hyperactivity/agitation and to the detection of alcohol, cannabis and 
amphetamines.   
Although there were some discrepancies between physician assessment and blood drug 
findings, there was no indication that any of these cases were severe unrecognized 
intoxications. The discrepancies could partly be explained by the many regular substance 
users in this sample that could have developed tolerance for high blood concentrations, or that 
they were misinterpreted as being influenced at the time of admission because of their general 
appearance (Box 3).  
Our findings could also indicate that physicians misinterpreted specific psychotic symptoms 
(hyperactivity/agitation) as drug related behaviour. The impact of the initial assessment on the 
discharge diagnosis in this study is not known. At discharge, however, many patients (10%) 
received the diagnosis of drug induced psychosis, although the length of hospital stay was 
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short and the etiology of psychosis is difficult to determine in the acute phase (192). 
Premature use of the label drug induced psychosis may obscure the diagnosis of an emerging 
serious mental illness (82, 103) (Box 4). Thus, the detection of recent substance intake and 
drug influence may have implications for immediate interventions (31), and may also have 
long-term implications: In busy acute wards, initial assessments may comprise the basis for 
diagnostic assessments at discharge and thereby influencing future treatment and referral 
strategies.   
Box 4 Case presentation, with status per 2010. 
 
 
 
 
 
 
 

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6.3. Clinical implications and future research 
The case presentation illustrates how challenging the initial assessments at the time of acute 
admissions can be (Box 3). A natural question for clinicians would be: Should comprehensive 
blood and urine analyses have priority among patients admitted to the acute psychiatric ward? 
The study has demonstrated some of the advantages of comprehensive laboratory testing, and 
when moderate or high prevalence of substance use is known or suspected, chromatographic 
methods could be considered for routine screening. In this project, the comprehensive 
laboratory analyses were rather slow and expensive. Now, by 2010, there are chromatographic 
methods providing quicker results for a lower cost, thus being more feasible in clinical 
settings. In assessing recent substance intake, urine analyses seem better than blood drug 
analyses because substances normally have longer detection times in urine than in blood. We 
During 2007, Joe’s health and socioeconomic situation were deteriorating further. He was repeatedly admitted to 
the acute ward, discharged after some days, and still unable or unwilling to take part in outpatient treatment or 
in-patient treatment elsewhere. Both staff in the social welfare office and in the acute ward agreed that his 
behaviour was now life-threatening and that immediate action was needed. In November, he was admitted for 
his 27th stay to the acute ward. As his condition was still supposed to be substance-induced, it was not possible 
to establish long-term compulsory assessment and treatment under the mental health law. However, it was 
decided to use the laws of social welfare, to transfer him with police for a long-term compulsory hospital stay in 
a locked ward for dual diagnosis patients.   
During a 4 months’ stay in the dual diagnosis unit and in the absence of drugs and alcohol, Joe was still having 
psychotic symptoms. At discharge, the main diagnosis was F20 Schizophrenia, and the secondary diagnosis was 
F10.9 Harmful use of multiple substances.  
With the diagnosis of a severe mental disorder, the treatment strategies were changed dramatically. Since 
February 2008 and to date (August 2010), Joe has lived in a well-staffed outpatient treatment centre, he has been 
under close supervision and compulsory long-term treatment with antipsychotic medication injected every 
second week. During these 30 months, his life has stabilized and he was admitted to the acute ward only once.       
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used quantitative blood drug analyses for the study of drug influence. In some cases, such 
analyses may provide useful diagnostic information at the time of acute psychiatric admission 
(Box 3). However, we do not see any reason to include blood drug screening as routine 
assessments in acute psychiatric wards. Drug influence should rather be included in the 
clinical assessments at the time of admission.  
During initial assessments, physician’s assessment, patient self-report and laboratory tests can 
be used in conjunction and have complementary roles. The different methods have their 
advantages and disadvantages as summarized in Table 9, and future studies are needed to 
define the proper way of combining these measures in acute psychiatric settings. The clinical 
utility and cost-efficiency of laboratory analyses could then be explored in greater detail, and 
different devices and methods should be tested simultaneously.  
The case presentation also illustrates how challenging the diagnostic evaluation at discharge 
can be (Boxes 2 and 4). Ever since his first admission, Joe was diagnosed with drug induced 
psychosis, and this may have obscured the diagnosis of an emerging serious mental illness. 
For substance-using patients admitted with first episode psychotic symptoms, the diagnosis of 
acute and transient psychotic disorder, unspecified, should be preferred (F23.9) (82). With 
regard to the important differential diagnosis of amphetamine induced psychosis and primary 
psychotic disorders, we are now planning another data collection. In a longitudinal multi-
centre study, patients with amphetamine-use and psychosis will be recruited in the acute ward, 
and assessed with several measures including laboratory methods and comprehensive 
diagnostic interviews, to possibly enhance the diagnostic accuracy.  
In this thesis, one-third of patients wanted help with their substance use behaviour. Obviously, 
there is a need for more evidence on effective interventions for substance using patients in 
acute care settings. A service program including screening, brief interventions and referral to 
treatment has shown very promising results with regard to substance use and related problems 
in a wide range of medical settings (110). Similar programs could be implemented and 
evaluated in acute psychiatric services as well.   
In an editorial on current issues in Scandinavian acute psychiatric wards, Ruud et al concludes 
that there is a need for development of higher standards of care and further research (8). It is 
our hope, that this study can contribute in improving the standards of care for patients 
admitted to acute psychiatric wards.   
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7. Conclusions 
The main results of the present study can be summarised in the following points: 
1. Patients acutely admitted to an inner city psychiatric ward in Oslo had high rates of 
recent substance intake. Amphetamines were especially common.   
2. Both patients and the physicians on call saw the current admission as being related to 
substance use in nearly half of the cases. One-third of the patients reported a need for 
professional help with regard to substance use.  
3. Recent alcohol intake was associated with suicidal behaviour and short hospital stay. 
Recent intake of illegal drugs was associated with psychosis and readmission. 
4. Recent substance intake was commonly under detected by the physician on call. This 
was especially pronounced for cannabis. 
5. On-site urine testing identified cannabis use that was not recognized by the 
physician’s initial assessment, although specificity for cannabis and benzodiazepines 
was low.  
6. Drug influence was present in one-fourth of the patients, both as assessed by the 
physician on call and by blood drug concentrations.  
7. Physician assessment showed a moderate positive relationship to the blood drug 
concentration scores and related also to symptoms of hyperactivity/agitation and to the 
detection of alcohol, cannabis and amphetamines.   
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9. Appendices  
 
Table A1 A selection of studies documenting prevalence rates of current co-occuring substance use disorders 
among patients consecutively admitted to acute psychiatric wards. 
 
 
DIS, Diagnostic Interview Schedule; SCID, Structured Clinical Interview for DSM-IV; ASI, Addiction Severity 
Index (ASI); AUDIT, Alcohol Use Disorder Identification Test; SCAN (Schedules for Clinical Assessment in 
Neuropsychiatry); SMAST, Short Michigan Alcohol Screening Test; DAST, Drug Abuse Screening Test; ICD-
10-R, International Classification of Diseases 10th edition, diagnostic criteria for research.  
a Study of male inpatients only.  
b Study of inpatients with psychotic disorders only. 
c Study of first time admissions only.   
d Stated as primary diagnosis at discharge. 
e Rates given for men / women.  

Reference  Country  N  Method for diagnosis Substance Any diagnosis  
of abuse or  
dependence (%) 
Ananth (1989) USA  75  DIS   Any 72 
Brady (1991) USA 100 SCID Any 29 
Wilkins (1991)a USA  56 Clinical diagnosis Any 23d  
Chen (1992) USA 104  Clinical diagnosis Any 30d 
Lehman (1994) USA 435  SCID Any 54 
Albanese(1994)b USA  89 SCID Any 30 
Appleby (1997) USA  375  Drake scale Any 45  
Dixon (1998) USA 268 SCID Any 41 
Reid (2004)c Trinidad 123  Clinical diagnosis Any 43 
Wheeler (2005) New Zealand 1232 Clinical diagnosis Any 27 
Galletly (1993) Australia  121 Clinical diagnosis Any 7 
Acuda (1997) Zimbabwe 194  AUDIT Alcohol 28 
Katz (2008) Israel 470 SCID Any 17 
Weich (2009)  South Africa 298 Clinical diagnosis Any  51 
Soyka (1993)b Germany 447 Clinical diagnosis Any 29 
Modestin(1997) Switzerland  417 Clinical diagnosis Any 48  
Bonsack (2006) Switzerland  266 Clinical diagnosis Any 39 
Ley (2002) UK  112  Clinical diagnosis Any 18d 
Barnaby (2003) UK  200  AUDIT  Alcohol 49 
Sinclair (2008) UK  178  AUDIT Alcohol 51/29e  
Preti (2008) Italy 1316 Clinical diagnosis Any 8d 
Xafenias (2008) Greece 313 ASI Any 33 
Nitschke (1995) Denmark 70 Clinical diagnosis Alcohol 39 
Hansen (2000) Denmark  376  SCAN Any  50 
Cruce (2007)b Sweden 241  AUDIT, DUDIT Any 25 
Møller (2004)b Norway  48 SMAST, DAST Any 56 
Øydna (2006) Norway  1533  Drake scale Any 47 
Ruud (2006) Norway 3572 Clinical diagnosis Any 7d 
Vaaler (2006) Norway 118 ICD-10-R Any 36  
Fløvig (2008) Norway  227  ICD-10-R Any 32 
Helseth (2009)b Norway  60 ASI, SCID Any 50 
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 Informasjon og samtykke
Forespørsel om deltakelse i forskning
Lovisenberg Diakonale Sykehus 
Nasjonalt Folkehelseinstitutt  
 
 
Vil du delta i forskningsprosjektet 
 
”Rus i akuttpsykiatrien”? 
 
 
Kjære nyinnlagte pasient! 
Mange psykiatriske pasienter bruker eller har brukt rusmidler. 
Sammenhengen mellom rus og psykisk helse er et viktig og komplisert 
felt hvor det ønskes mer kunnskap. Derfor spør vi om du vil bli med i et 
forskningsprosjekt hvor vi skal undersøke dette nærmere. Vi ønsker å 
kartlegge psykisk helse og rusvaner hos alle nyinnlagte pasienter ved 
akuttpsykiatrisk avdeling. Det er viktig at både pasienter som bruker og 
ikke bruker rusmidler deltar. Ved din deltakelse vil du gi et verdifullt 
bidrag til et forskningsprosjekt som ønsker å bidra til bedre utredning og 
behandling i akuttpsykiatrien.  
    
Studieinnhold 
1) Vi ber om tillatelse til å hente opplysninger fra din journal til bruk i 
forskningsprosjektet. 
2) Vi ber om tillatelse til å intervjue deg om din psykiske helse og dine 
rusvaner. Intervjuene varer cirka en time og gjøres i løpet av 
oppholdet her.   
3) Ved innleggelsen ble det rutinemessig tatt blodprøve og urinprøve. 
Vi ber om tillatelse til å analysere prøvene med hensyn til 
rusmidler.  
 
Datasikkerhet 
1) Medarbeiderne i prosjektet har taushetsplikt, og all informasjon om 
deg vil bli behandlet konfidensielt. Personlige opplysninger vil kun 
brukes til forskning og vil ikke kunne kobles til deg.  
2) Blodprøvene og urinprøvene analyseres og oppbevares ved 
Nasjonalt Folkehelseinstitutt. Der opprettes det en egen biobank 
for dette prosjektet, som divisjonsdirektøren er ansvarlig for. 
Prøvene er ikke tilgjengelig for noen andre. Analysene tar noe tid, 
og svarene vil kun brukes til forskning. Prøvesvarene blir derfor 
ikke tilgjengelig for deg, din behandler eller din journal.     
3) Intervjuene med deg vil også gi viktig informasjon. Du har rett til å 
få innsyn i disse opplysningene og til å få noe endret hvis det er 
feil. Denne informasjonen legges i journalen din, og kan være 
nyttig for din behandling.  
 Informasjon og samtykke
Forespørsel om deltakelse i forskning
Lovisenberg Diakonale Sykehus 
Nasjonalt Folkehelseinstitutt  
 
 
 Rekvirere blodprøver så snart som mulig (ø-hjelp, ”prosjekt”). Obs! Trengs suppl. undersøkelser? 
Du skal ikke informere om prosjektet i innkomstsituasjonen. Dette gjøres senere. Legg ferdig utfylt 
skjema i medisinkardex for aktuelle pasient, og kryss av i ”sjekkliste”. TAKK FOR SAMARBEIDET! 
Innkomst-skjema ”Rus i akuttpsykiatrien 2006”Lovisenberg Diakonale Sykehus Nasjonalt folkehelseinstitutt   
 
Spørsmål til mottagende lege: 
Skal besvares for alle nyinnlagte pasienter 
(Se viktig informasjon helt nederst) 
 
 
 
 
 
 
          
 
 
 
På bakgrunn av alle tilgjengelige data ved innkomstvurdering 
 
1) I løpet av den siste uken og ved innkomstvurdering: I hvilken 
grad har pasienten hatt positive symptomer?  
(Markér høyeste score i denne perioden, se PANSS –veil. på baksiden) 
 
Vrangforestillinger              1     2     3     4     5     6     7 
Tankemessig desorganisering     1     2     3     4     5     6     7 
Hallusinasjoner    1     2     3     4     5     6     7 
Uro / agitasjon    1     2     3     4     5     6     7 
Storhetsidéer    1     2     3     4     5     6     7 
Mistenksomhet / forfølgelsesidéer 1     2     3     4     5     6     7 
Fiendtlighet     1     2     3     4     5     6     7 
 
2) Opplysninger om aktuelt inntak av rusmidler (kryss av) 
 Alkohol      Amfetamin  Organisk løsemiddel 
 Benzodiazepiner  Kokain      Annet rusmiddel:____ 
 Cannabis   Morfin / heroin   Ingen opplysninger 
Hvis opplysninger om dette:  
Stoff, mengde, tidspunkt, inntaksmåte: __________________________________ 
 
3) I hvilken grad opplever du at pasienten er påvirket av 
rusmidler ved innkomst? (kryss av) 
 Ikke påvirket            Moderat påvirket   
 Lett påvirket    Tydelig påvirket    Ikke mulig å bedømme 
  
4) Hvordan vurderer du rusmidlers betydning for innleggelsen?   
 Ingen betydning            Stor betydning   
 Moderat betydning  Ikke mulig å bedømme
  
Dato og tidspunkt:   ____________________            
Signatur, mottakende lege: __________________               
Plasser pasientetikett her 
 
Eventuelt skriv med blokkbokstaver: 
 
Pas. navn:  ______________ 
F. nummer: _______________ 
 
Dato og tidspunkt for 
innkomstundersøkelse 
 
_____________ 
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Velkommen til Lovisenberg Diakonale Sykehus! 
 
Spørsmål til alle pasienter ved akuttpsykiatrisk avdeling 
 
Vi ønsker i størst mulig grad å forstå din situasjon og dine eventuelle helseproblemer. Derfor håper vi 
du kan samarbeide om å svare på noen spørsmål om dette. Utfyllingen tar cirka 15 minutter, og vil 
være til stor hjelp for oss. Bare spør personalet ved behov. Takk for hjelpen! 
 
 
Navn:   _____________________ 
 
Fødselsdato:  _____________________ 
 
Dato i dag:  _____________________ 
 
 
Under finner du en liste over ulike problemer. 
Har du opplevd noe av dette den siste uken (til og med i dag)? 
 
                              Ikke           Litt         Ganske            Veldig 
Sett et kryss på hver linje                                plaget         plaget            mye           mye 
 
1. Plutselig frykt uten grunn          
2. Føler deg redd og engstelig          
3. Matthet eller svimmelhet           
4. Føler deg anspent eller oppjaget         
5. Lett for å klandre deg selv          
6. Søvnproblemer           
7. Nedtrykt, tungsindig           
8. Følelse av å være unyttig, lite verd          
9. Følelse av at alt er et slit          
10. Følelse av håpløshet mht. framtida         
11. Har tanker om å ta ditt eget liv         
 
Om alkohol og stoff/narkotika                                                                                                  Slett ikke   Delvis    Svært mye 
12. Tror du bruk av alkohol eller stoff har hatt betydning for innleggelsen her?         
13. Synes du at du trenger profesjonell hjelp for å forandre din alkoholbruk?                            
14. Synes du at du trenger profesjonell hjelp for å forandre ditt stoffbruk?                         
 
Om pengespill (eks. spilleautomater og tipping)           Ja       Nei 
15. Har du noen gang følt behov for å spille for mer og mer penger?                        
16. Har du noen gang løyet for mennesker som er viktige for deg, om hvor mye du spiller?       
 
Om tobakk                Ja       Nei 
17. Røyker du sigaretter eller bruker du snus?                      
18. Hvis ja: Hvor mange sigaretter røyker du vanligvis per dag? ____ Evnt. snusdoser per dag? ____ 
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Her er noen spørsmål om din bruk av alkohol siste 12 måneder 
 
 
1. Hvor ofte drikker du alkohol? 
 
Aldri 
 
 
Månedlig eller 
sjeldnere 
 
2-4 ganger i 
måneden 
 
2-3 ganger 
i uken 
 
4 ganger i 
uken eller mer 
 
 
2. Hvor mange alkoholenheter tar 
du på en typisk drikkedag? 
(En alkoholenhet er: 1 glass vin, 
1 drink, en liten flaske pils, 0,33 l) 
 
1-2  
 
 
3-4   
 
 
5-6  
 
 
7-9  
 
 
10 eller flere 
 
 
 
3. Hvor ofte drikker du seks 
alkoholenheter eller mer på en 
gang?  
Aldri 
 
 
 
Sjeldnere enn 
månedlig 
 
 
Noen ganger  
i måneden  
 
 
Noen 
ganger i 
uken 
 
Daglig eller 
nesten daglig 
 
 
 
4. Hvor ofte har du i løpet av det 
siste året ikke vært i stand til å 
stoppe og drikke alkohol etter at 
du hadde begynt? 
Aldri 
 
 
 
Sjeldnere enn 
månedlig 
 
 
Noen ganger  
i måneden 
 
 
 
Noen 
ganger i 
uken 
 
Daglig eller 
nesten daglig 
 
 
5. Hvor ofte har du i løpet av det 
siste året unnlatt å gjøre ting du 
skulle gjort på grunn av drikking? 
Aldri 
 
 
 
Sjeldnere enn 
månedlig 
 
 
Noen ganger  
i måneden 
 
 
Noen 
ganger i 
uken 
 
Daglig eller 
nesten daglig 
 
 
 
6. Hvor ofte har du i løpet av det 
siste året trengt en drink om 
morgenen for å komme i gang 
etter sterk drikking dagen før?  
Aldri 
 
 
 
Sjeldnere enn 
månedlig 
 
 
Noen ganger  
i måneden 
 
 
Noen 
ganger i 
uken 
 
Daglig eller 
nesten daglig 
 
 
 
7. Hvor ofte har du i løpet av det 
siste året hatt skyldfølelse eller 
samvittighetsnag på grunn av 
drikking?  
Aldri 
 
 
 
Sjeldnere enn 
månedlig 
 
 
Noen ganger 
i måneden 
 
 
Noen 
ganger i 
uken 
 
Daglig eller 
nesten daglig 
 
 
 
8. Hvor ofte har du i løpet av det 
siste året ikke husket hva som 
hendte kvelden før på grunn av 
drikking? 
 
Aldri 
 
 
 
Sjeldnere enn 
månedlig 
 
 
Noen ganger  
i måneden 
 
 
Noen 
ganger i 
uken 
 
Daglig eller 
nesten daglig 
 
 
 
9. Har du eller noen andre blitt 
skadet som følge av drikkingen 
din? 
Nei 
 
 
 Ja, men ikke 
det siste året 
 
     Ja, det siste  
året 
 
 
10. Har en slektning eller venn, 
lege eller sykepleier, eller noen 
andre engstet seg over 
drikkingen din, eller antydet at du 
burde redusere?  
 
Nei 
 
 
 
 Ja, men ikke i 
løpet av siste 
år 
 
 Ja, i løpet av 
siste år 
 
 
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Her er noen spørsmål om stoff 
 
 
1. Hvor ofte bruker du andre stoff  
enn alkohol? Se listen over stoff 
på neste side, og kryss av. 
 
Aldri 
 
 
1 gang i måneden 
eller sjeldnere 
 
2-4 ganger i 
måneden 
 
2-3 ganger 
i uken 
 
4 ganger i 
uken eller mer 
 
 
2. Bruker du flere enn ett stoff 
ved ett og samme tilfelle? 
Aldri 
 
 
1 gang i måneden 
eller sjeldnere 
 
2-4 ganger i 
måneden 
 
2-3 ganger 
i uken 
 
4 ganger i 
uken eller mer 
 
 
3. Hvor mange ganger i løpet av 
en typisk dag tar du stoff, når du 
tar stoff?  
 
0 
 
 
1-2 
 
 
3-4 
 
 
5-6 
 
 
7 eller flere 
 
 
4. Hvor ofte blir du kraftig 
påvirket av stoff? 
Aldri 
 
 
 
Sjeldnere enn en 
gang i måneden 
 
 
Hver 
 måned 
 
 
 
Hver  
uke 
 
 
Daglig eller 
nesten daglig 
 
 
5. Har du det siste året opplevd 
at lengselen etter stoff har vært 
så sterk at du ikke kunne stå 
imot? 
 
Aldri 
 
 
 
Sjeldnere enn en 
gang i måneden 
 
 
Hver  
måned 
 
 
Hver  
uke 
 
 
Daglig eller 
nesten daglig 
 
 
 
6. Har det hendt at du i løpet av 
siste året ikke kunne slutte å ta 
stoff når du først hadde begynt?  
Aldri 
 
 
 
Sjeldnere enn en 
gang i måneden 
 
 
Hver 
 måned 
 
 
 
Hver  
uke 
 
 
Daglig eller 
nesten daglig 
 
 
 
7. Hvor ofte i løpet av det siste 
året har du tatt stoff og så latt 
være å gjøre noe som du burde 
ha gjort?  
Aldri 
 
 
 
Sjeldnere enn en 
gang i måneden 
 
 
Hver 
 måned 
 
 
 
Hver  
uke 
 
 
Daglig eller 
nesten daglig 
 
 
 
8. Hvor ofte i løpet av det siste 
året har du hatt behov for å starte 
dagen med å ta stoff etter stort 
stoffinntak dagen før? 
 
Aldri 
 
 
 
Sjeldnere enn en 
gang i måneden 
 
 
Hver 
 måned 
 
 
 
Hver  
uke 
 
 
Daglig eller 
nesten daglig 
 
 
 
9. Hvor ofte i løpet av det siste 
året har du hatt skyldfølelse eller 
dårlig samvittighet fordi du har 
brukt stoff? 
 
Aldri 
 
 
 
Sjeldnere enn en 
gang i måneden 
 
 
Hver 
 måned 
 
 
 
Hver  
uke 
 
 
Daglig eller 
nesten daglig 
 
 
 
10. Har du eller noen andre blitt 
skadet (psykisk eller fysisk) på 
grunn av din bruk av stoff?  
 
Nei 
 
 
 
 
 Ja, men ikke i 
løpet av det 
siste året 
 
 Ja, i løpet av 
det siste året 
 
 
11. Har en slektning eller venn, 
lege eller sykepleier, eller noen 
andre vært urolige for din bruk av 
stoff, eller sagt til deg at du bør 
slutte med stoff?  
Nei 
 
 
 
 Ja, men ikke i 
løpet av det 
siste året 
 
 Ja, i løpet av 
det siste året 
 
 
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LISTE OVER STOFF (ikke alkohol) 
 
Sett et kryss ved de stoffene du eventuelt har brukt 
 
 
Cannabis 
 
 
Amfetaminer 
 
Kokain 
 
Opiater 
 
Hallusinogener 
 
Løsningsmidler 
GHB og 
andre 
Marihuana 
Hasj 
Cannabisolje 
Amfetamin 
Metamfetamin 
Khat 
Ritalin 
Dexamin 
Crack 
Kokablad 
Heroin 
Røyke-
heroin 
Opium 
 
Ecstasy (MDMA) 
LSD 
Meskalin 
PCP (englestøv) 
Fleinsopp 
Tynner 
Bensin 
Gass 
Løsemidler, lim 
Trikloretylen 
 
GHB 
Anabole 
steroider 
Lystgass 
Amylnitritt 
 
 
Ved ett eller flere kryss: 
Hvilket stoff har du brukt mest det siste året?   ______________________ 
Når tok du dette stoffet sist?    ______________________ 
Hvilke stoff har du eventuelt brukt den siste uken?   ______________________  
 
 
 
 
TABLETTER – LEGEMIDLER 
 
Tabletter regnes som stoff når du tar: 
 legemidler mer eller oftere enn legen har foreskrevet 
 tabletter for å ha det moro, føle deg bra, bli ”høy”, eller prøve ut effekten  
 tabletter som du har fått en slektning eller en venn  
 tabletter som du har kjøpt ”svart” eller stjålet 
 
Sett et kryss ved de tablettene du eventuelt har brukt som beskrevet over 
 
 
Beroligende legemidler / sovetabletter 
 
 
Smertestillende legemidler 
Alopam 
Alprazolam  
Apodorm  
Barbital  
Dormicum 
Fenemal  
Flunipam  
Heminevrin  
 
Imovane  
Mogadon  
Rivotril  
Rohypnol  
Sobril  
Somadril  
Stesolid  
 
Stilnoct  
Valium  
Vival  
Xanor  
Xanor dep.  
Zolpidem  
Zopiklon 
 
Andre: 
Disipal 
Akineton 
 
Actiq                     
Aporex  
Anervan  
Buprenorfin  
Cosylan  
Dolcontin  
Durogesic  
Etylmorfin  
Fentanyl  
Fortralin  
Hydrokon 
Ketalar 
Ketamin 
Ketogan 
Ketorax 
Kodein 
Metadon 
Modiodal 
Morfin 
Morfin-
skopolamin 
 
Nobligan 
OxyContin  
OxyNorm  
Paralgin  
Petidin  
Pinex  
Subutex  
Temgesic  
Tradolan  
Tramadol  
Tramagetic  
 
 
Husk at tabletter regnes ikke som stoff når de er foreskrevet av lege, og du tar dem slik legen sier at 
du skal (både mengde og hyppighet).  
 
 
 
Takk for at du har besvart våre spørsmål! 
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Abstract 
Background: Estimates of psychoactive substance use among acutely admitted psychiatric 
patients vary among studies, and few have used comprehensive laboratory methods. Aims: 
This study used chromatography-based analyses of blood and urine to identify the rates of 
substance use among acute psychiatric admissions, and to study the associations with 
sociodemographic variables, clinical characteristics and patients' reports of symptoms, 
substance use and need for treatment. Methods: A cross-sectional study was conducted in 
2006/2007 in Oslo, Norway. Blood and urine samples were collected from 298 acute 
psychiatric admissions and extensively analyzed for alcohol, medicinal and illicit drugs. 
Psychotic symptoms were assessed with the positive subscale of the Positive and Negative 
Syndrome Scale. Patient self-report questionnaires included the Alcohol and Drug Use 
Disorder Identification Tests. Patients were also asked if they needed professional help for 
substance use. Results: Psychoactive substances were detected in 63% of the 298 admissions, 
medicinal drugs in 46%, alcohol in 12% and illicit drugs in 28%. Patients using alcohol had a 
high suicidal risk score at admission and the shortest length of stay (median one day). Use of 
illicit drugs was associated with psychotic symptoms and readmission. Self-report 
questionnaires indicated harmful use of alcohol for half of the patients and of other substances 
for one-third. A need for professional help for substance use was reported by one-third of 
patients. Conclusion: Given the high rates of substance use and the important clinical 
associations, drug screening seems warranted in acute psychiatric settings. Interventions 
designed for substance-using patients should be developed and integrated.    
 
Keywords: Substance use, alcohol, illicit drugs, toxicology, psychiatric inpatients.  
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Background 
Recent intake of alcohol and medicinal or illicit drugs is common among patients in acute 
psychiatric settings, and may influence symptoms, treatment and prognosis (1, 2). Substance-
using patients constitute a heterogeneous group. Some have primary substance-induced 
disorders, whereas others have primary mental disorders complicated by substance use (3), 
and patients’ awareness of illness and perceived need for treatment vary (4). Such distinctions 
have clear implications for treatment (2). Identifying substance-using patients may be difficult 
in the acute phase, however, as symptoms of substance use can mimic many psychiatric 
disorders. Substance use detection is commonly undertaken through clinical interviews, 
patients’ self-reports or toxicological tests.  
 European and US studies using toxicological analyses among acutely admitted psychiatric 
patients report frequencies ranging from 20% to 72% (5-14). Most of these studies were 
conducted in urban clinics, but the broad range may be partly explained by different substance 
use patterns across regions and countries. In addition, there are methodological differences 
that make comparisons across studies problematic. Many studies have included only a limited 
number of drugs, such as benzodiazepines (12) and cocaine (13). Some have studied groups 
of patients known to have high rates of substance use: men (14) or young psychotic patients 
(9), for example. Studies also exhibit variation in the methods used for substance detection. 
Urine samples have commonly been screened with immunoassay techniques, which have 
limited sensitivity and specificity, and not all substances can be detected (15). Thus, many 
studies lack detailed information on recent substance intake and polydrug use.  
 Identification and adequate management of substance-related conditions are critical in the 
clinical setting, and precise measures are required for epidemiological, surveillance and 
planning purposes. In acute psychiatric settings, few studies have used comprehensive 
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laboratory methods for assessing substance use, and little is known about the 
sociodemographic and clinical associations of toxicological findings among patients admitted 
to acute psychiatric wards. 
 
Aims 
This study investigates recent intake of alcohol and medicinal and illicit drugs among patients 
hospitalized in an urban Norwegian acute psychiatric ward. The study uses chromatography-
based laboratory analyses of blood and urine to identify a wide range of psychoactive 
substances, and to estimate the level of nonprescribed use of medicinal drugs. Admissions 
were divided into four groups according to laboratory findings (no drugs detected, medicinal 
drugs only, alcohol and illicit drugs). These groups were compared with regard to 
sociodemographic variables, clinical characteristics and patients’ reports of symptoms, 
substance use and need for treatment. 
5 
 
Material and methods 
Participants 
This cross-sectional study was conducted between September 2006 and February 2007 in a 
public hospital in Oslo, Norway, serving approximately 100,000 inner-city inhabitants. 
Consecutively admitted patients who were willing to participate in the study provided written 
informed consent. Of the 351 acute admissions, 298 (85%) were included in the study, 33 
(9%) declined, 12 (3%) did not provide biological specimens for drug analysis and 8 (2%) 
were excluded because of dementia. The study sample comprised 220 patients admitted once 
and 32 patients admitted twice or more. The mean age of included patients was 39 years (SD 
15); 47% were males, and 44% were admitted to the ward for the first time. The median 
length of hospital stay was 5 days (range 0-111). We found no difference between those 
included and those not included in the study sample on age (P = 0.94), gender (P = 0.91) and 
length of stay (P = 0.57), but nonparticipants were more often admitted on an involuntary 
basis (82% vs. 56%, P < 0.001). To evaluate the representativeness further, participants were 
compared with all 1133 admissions to the same Oslo unit during 2006 and with a national 
sample of more than 3500 acute psychiatric admissions from a multicentre study performed in 
2005 (16). In these comparisons, no differences were found in age, gender or length of stay (P 
> 0.2). As compared with the national sample, however, participants were more often of non-
Norwegian origin (20% vs. 10%), homeless (10% vs. 4%), involuntarily admitted (55% vs. 
42%) and had a substance use disorder as discharge diagnosis (45% vs. 22%) (P < 0.001 for 
all).  
 
Laboratory measures 
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Blood and urine samples were collected as soon as possible after admission. Admissions 
during which at least one sample was obtained within 48 hours were included in this study. 
Samples were brought on a weekly basis to the Division of Forensic Toxicology and Drug 
Abuse, Norwegian Institute of Public Health. Using the enzyme multiplied immunoassay 
technique (EMIT), all urine samples were screened for substances and their metabolites: 
benzodiazepines, opiates, amphetamines (amphetamine, methamphetamine and ecstasy), 
cocaine, cannabis, methadone, buprenorphine, dextropropoxyphene, barbiturates, 
phencyclidine and lysergic acid diethylamide (LSD) (Table 1). Blood samples were screened 
with EMIT for opiates, amphetamines, cocaine and cannabis, and by liquid chromatography-
mass spectrometry for benzodiazepines, hypnotics, carisoprodol, meprobamate and 
methadone. Blood samples were screened for alcohol with an enzymatic dehydrogenase 
method, as were the urine samples of patients who did not provide blood. All positive 
screening results in urine and blood were confirmed by gas or liquid chromatography-mass 
spectrometry, with cut-off values presented in a previous paper (11).  
 Laboratory results were used only for study purposes, and were available for the 
researchers at the end of the data collection period. Both blood and urine analyses were used 
to increase the number of detectable substances (e.g. zopiclone was detected only in blood 
and LSD only in urine). It also increased the inclusion rate, as some patients provided only 
blood or only urine specimens. Except for benzodiazepines or opiates that had been 
prescribed after admission, substances were reported as present if they were detected in the 
blood or urine. Only one finding was counted if both the parent drug and its metabolites were 
detected. Morphine and codeine were defined as medicinal drugs unless the heroin metabolite 
6-monoacetylmorphine (6-MAM) was also found. The benzodiazepine, phenazepam, was 
defined as an illicit drug, as it was neither registered nor sold in Norway.  
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 To study the associations between laboratory findings and sociodemographic and clinical 
variables, we divided the study sample into four groups; 1) no drugs detected, 2) medicinal 
drugs only, 3) alcohol without illicit drugs (with or without medicinal drugs) and 4) illicit 
drugs (with or without alcohol and medicinal drugs). A retrospective review of medical 
records assessed whether or not findings of medicinal drugs represented prescribed use before 
admission. Reviewed documents included notes from the admitting physician and the nurse 
and physician on call, as well as the inpatient prescription form. If the specific laboratory 
finding could be explained by a prescription that was documented in the medical records, it 
was defined as “prescribed use”. Other positive findings not documented were defined as 
“nonprescribed use”, as were findings in which patients reported non-therapeutic use at the 
time of admission.  
 
Sociodemographic variables, clinical characteristics and patient self-report 
Sociodemographic and clinical variables for the study sample were also obtained by the 
review of medical records. The variables included age, gender, education level, 
accommodation type, employment status, number of previous psychiatric admissions, and the 
legal status of the admission, suicidal risk at admission, use of coercion (seclusion, coercive 
medication and manual restraints) and ICD-10 discharge diagnoses (Table 2). Suicidal risk at 
admission was assessed by rating patients on a scale from 1 to 6, where 1 = ‘no risk’ and 6 = 
‘recent severe self-harm with obvious intention to die’ (17). Symptom severity and social and 
occupational functioning were measured by clinicians using the split version of the Global 
Assessment of Functioning (GAF) scale (18, 19). Psychotic symptoms at the time of 
admission were assessed by the physician on call using the positive subscale of the Positive 
and Negative Syndrome Scale (PANSS) (20). Standardized questionnaires were administrated 
8 
 
to the patients. The 10-item Hopkins Check List (HSCL-10) was used to measure symptoms 
of anxiety and depression during the last week (21). This instrument has demonstrated good 
sensitivity and specificity as compared with the widely used HSCL-25 (22). The 10-item 
Alcohol Use Disorder Identification Test (AUDIT) (23) and the 11-item Drug Use Disorder 
Identification Test (DUDIT) (24) were used to measure substance use patterns during the last 
year. All items were scored from zero to four. AUDIT scores of 8 for men and 5 for women 
were used as cut-off scores for harmful alcohol use, and DUDIT scores of 6 for men and 2 for 
women were used as cut-off scores for harmful use of medicinal or illicit drugs (24, 25). 
Patients were also asked about their tobacco use and asked, “Do you think you need 
professional help to change your alcohol use?” and “Do you think you need professional help 
to change your drug use?” (Not at all / partly / totally). The latter question is part of the Drug 
Use Disorders Identification Test-Extended (DUDIT-E) (26). Patients and physicians on call 
were also asked “Do you think that the current admission was related to substance use?” (Not 
at all / partly / totally). The results of patient self-reports and physician assessments were 
documented in medical records. The study was approved by The Regional Committee for 
Medical Research Ethics and the Norwegian Data Inspectorate. 
 
Statistical analyses 
Count data are presented as numbers (%), and the overall detection rates are presented with 
95% confidence intervals (CI). Continuous data with approximate normal distributions are 
presented as means (SD) and non-normal data as medians (range). For comparisons of two 
groups, a 2 test was used for dichotomous dependent variables, and Student’s t-test or Mann 
Whitney U-test for continuous dependent variables. We used a significance level of 0.05. 
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 The four drug groups (no drugs, medicinal drugs only, alcohol without illicit drugs and 
illicit drugs) were compared with regard to sociodemographic and clinical variables, using 
Bonferroni corrections for multiple comparisons (P < 0.002). For dichotomous dependent 
variables, post-hoc pairwise comparisons among all subgroups were Bonferroni corrected 
with a significance level of 0.009. Normally distributed continuous variables were analyzed 
with one-way analysis of variance (ANOVA), and post-hoc comparisons were performed 
using the Tukey HSD test. Kruskall-Wallis tests were used for non-normal data, with Mann-
Whitney tests and Bonferroni corrections for post-hoc pairwise comparisons.   
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Results 
Urine and blood samples were obtained from patients in 246 (83%) of the 298 admissions. 
Blood samples only were obtained from 41 (14%) and urine only from 11 (4%). Blood 
samples were taken at a median of 30 minutes after admission (range 0-48 hours) and urine 
samples after 7 hours (0-95 hours). In 284 admissions (95%), either blood or urine was 
obtained within 24 hours. Physician assessments were performed for 285 (96%) admissions 
after a median of 30 minutes (range 0-6 hours). Of the 252 patients included in the study, self-
report questionnaires were completed by 230 (91%), usually at the day of admission (median 
0, range 0-30 days).  
 Psychoactive substances were detected in 187 (63%) (95% CI 57 - 68%) of the 298 
admissions, medicinal drugs in 46% (41 - 52%), alcohol in 12% (9 - 16%) and illicit drugs in 
28% (23 - 33%) (Table 1). Altogether, 20 different substances were detected, with two or 
more drug findings in 135 (42%) of the admissions. Up to 10 substances were found in 
specimens from one patient. Of the medicinal drugs, diazepam was the most common (34%) 
(95% CI 29 - 39%). Of the illicit drugs, cannabis was found in 18% (14 - 23%) and 
amphetamines in 16% (12 - 20%) of the admissions. Cocaine was rare (2%) (0 - 4%), and 
barbiturates, ecstasy, phencyclidine, GHB, and LSD were not detected in this population.  
 Admissions were divided into four groups according to laboratory findings. Patients 
positive for illicit drugs had a median of 2 detected substances, including 16 of the 19 cases 
with flunitrazepam, and 9 of the 10 cases with methadone (Table 1). Nonprescribed use of 
medicinal drugs was estimated for a total of 108 admissions (36%), with 66% in the medicinal 
drug group, 44% in the alcohol group and 55% in the illicit drug group. Flunitrazepam, 
methadone and morphine were used without prescription in more than 80% of the positive 
cases, all with median numbers of drug findings 4 or above (data not shown).  
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< Table 1 about here > 
 
Drug groups were compared with regard to clinical characteristics (Table 2) and 
sociodemographic variables. No significant relationships were found with HSCL-10 scores, 
previous psychiatric admission and employment status (data not shown). Patients with 
negative tests and with medicinal drugs only did not differ significantly from the other groups 
on any variable in the post-hoc analyses. The current admission was seen as being partly or 
totally related to substance use by 42% of patients completing the questionnaire and by 45% 
of physicians on call, with the highest percentages found in the alcohol group and the illicit 
drug group. Harmful use of alcohol was reported by half of all patients; by all patients in the 
alcohol group and by 44% of the patients in the other groups. Harmful use of other substances 
was reported by one-third of all patients; by 78% in the illicit drug group and by 19% of the 
other patients. A need for professional help with regard to substance use was reported by 31% 
of patients (alcohol use 12%, drug use 12% and both 7%), with the highest percentages found 
in the alcohol group and the illicit drug group.  
 
< Table 2 about here > 
 
Patients in the alcohol group had the shortest hospital stay (median 1 day) and the highest 
percentage of alcohol use disorders (59%), compared to all other groups (P < 0.002). Patients 
positive for alcohol also had a higher suicidal risk score than did patients in groups of no 
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drugs (P = 0.022) and illicit drugs (P = 0.006), but not significantly higher than those with 
medicinal drugs only (P = 0.57).  
 Patients who were positive for illicit drugs had the lowest GAF score at admission (P < 
0.03 in post-hoc ANOVA) and the highest percentages of disorders due to multiple substance 
use (56%) (P < 0.001), compared to all other groups. Compared to patients in the medicinal 
drugs and alcohol groups, patients who were positive for illicit drugs had the highest scores 
for positive psychotic symptoms (PANSS scores) (P < 0.002), and were more often admitted 
on an involuntary basis (P < 0.009). Compared to patients in the no drugs and medicinal drugs 
groups, patients positive for illicit drugs were more often men (66% vs. 42% and 32%), 
homeless (24% vs. 5% and 4%), tobacco users (95% vs. 64% and 59%), and had less 
education (76% had primary school or less, vs. 41% and 47%) (P < 0.009 for all post-hoc 
tests). When these variables were compared with patients in the alcohol group, the same 
tendencies were observed (P = 0.02 - 0.05), but the differences were not significant after 
Bonferroni correction.  
 The 32 patients with readmissions did not differ from other patients with regard to age (P = 
0.70) and gender (P = 0.41), whereas detection of illicit drugs (39% vs. 25%, P = 0.019) and 
drug-related discharge diagnoses (65% vs. 37%, P < 0.001) were more common among 
readmitted patients (data not shown). Twelve patients had different laboratory findings upon 
readmission, and were therefore represented in two drug groups.   
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Discussion  
Recent intake of psychoactive substances with potentially impairing effects was widespread 
among patients acutely admitted to this inner city psychiatric hospital in Oslo. Almost two-
thirds of the sample was positive for at least one psychoactive substance. A total of 20 
different substances were detected, with up to ten in a single patient. Both patients and the 
physicians on call saw the current admission as being related to substance use in nearly half of 
the cases. Self-report questionnaires indicated harmful alcohol use for half of the patients and 
harmful use of other drugs for one-third. A need for professional help for substance use was 
reported by one-third of patients. All these findings demonstrate the major impact of both 
recent and long-term substance use and the need for tailored interventions for substance-using 
patients in acute psychiatric wards. 
 The identification of risk factors of substance use can contribute to improved detection of 
substance-using patients. Patients positive for illicit drugs at admission, as compared to 
patients with drug-free samples, were more often men, homeless, less educated and tobacco 
users. These results correspond with previous inpatient studies using urine toxicology (7) and 
self-reports (5, 10). The use of illicit drugs was also associated with lower levels of general 
functioning (low GAF scores) and increased problems with psychosis and readmissions. 
These patients constitute a large and marginalized group calling for clinical concern. 
Amphetamines, which were detected in one-sixth of patients, are particularly associated with 
serious negative health effects (27) and may have a major impact on emergency services (28).  
 Alcohol-positive patients had a high suicidal risk score at admission. The relationship 
between acute alcohol intake and suicidal risk has been described previously (29). Taken 
together, these studies suggest that acutely admitted patients with both substance use and 
suicidal behaviour require specialized focus (17). Our results support the association between 
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substance use and shorter hospital stay (5, 8), and this finding may be especially the case for 
patients who are admitted under the influence of alcohol. Due to rapid elimination of alcohol, 
patients may leave the unit because of rapid recovery or unpleasant withdrawal symptoms.  
We found that benzodiazepines and other medicinal drugs were often nonprescribed, and 
that nearly all patients with findings of flunitrazepam and methadone also tested positive for 
illicit drugs. Even if the rate of nonprescribed use may have been overestimated due to 
omissions or inadequacies in the medical records, this finding suggests a widespread abuse of 
medicinal drugs among these patients. Use of benzodiazepines and opiates should be carefully 
monitored in the treatment of psychiatric patients, and toxicological screening tests may help 
in detecting undeclared use of these drugs (30).  
The percentage of included admissions was high (85%), and we assume that our findings 
are representative for patients admitted to this hospital. The substance use in this sample is not 
nationally representative, because of its higher rate of substance use disorders (16). This 
finding may be explained partly by higher rates of substance use in the general population of 
Oslo than in other parts of Norway (31), and in the inner city population in particular. Bearing 
in mind the geographical differences in acute psychiatric services (32) and methodological 
differences across studies, detection rates of specific substances are compared in the following 
paragraph with those of other studies from urban clinics in Europe and USA. Comparison is 
also challenged by the lack of confidence intervals in previous studies.  
 High detection rates were found for most substances in this study. The benzodiazepine rate 
of 43% (95% CI 38 - 49%) is in the upper range of previous reports (7% - 45%) (6, 8-12), 
which may be partly explained by our use of comprehensive and sensitive laboratory 
methods. Detection of alcohol in blood or urine indicates recent consumption (most likely 
during the last 12 hours), and the rate of 12% (95% CI 9 - 16%) seems higher than the few 
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previous figures available from other studies (2% and 6%) (8, 9). The rate of illicit drugs 
(28%, 95% CI 23 - 33%) is similar to recent reports from Switzerland and France (20% and 
26%) (5, 7). For amphetamines, the rate of 16% corresponds with previous studies among 
inpatients in Oslo (17% and 22%) (9, 11), whereas others have reported frequencies of 5% or 
less (7, 8, 14). In contrast, cocaine was rarely found in this sample (2%) as compared to US 
samples (29% - 50%) (6, 13, 14), probably reflecting differences in substance use across 
countries.  
 An interpretation of our results should take the limitations of the study design into account. 
First, the study was conducted in a busy ward with many severely ill patients, and the quality 
of such non-laboratory data as the assessment of suicidal risk and perceived treatment need 
was suboptimal. For example, the assessment of prescribed medication was based on a review 
of medical records. Although medication history taking is mandatory at acute admissions, it 
may be limited by patients’ memory problems, poor record-keeping, and, especially for 
patients admitted for the first time, a general lack of information. Second, for some patients, 
only blood samples were obtained. As most substances are rapidly eliminated from blood 
(33), it is likely that a few cases of recent substance use were not detected. Third, alcohol is 
rapidly removed from the body, and additional biomarkers with longer detection times, such 
as ethyl glucoronide or carbohydrate deficient transferrin, could have added valuable 
information and increased the estimates of recent alcohol users. Few admissions in the alcohol 
group reduced the statistical power of subgroup analyses. Finally, the division of the patients 
into four drug groups raised several methodological concerns. To distinguish users of alcohol 
and illicit drugs is common, whereas classifying patients with medicinal drugs only into one 
group has not previously been done. Relatively large and heterogeneous groups may increase 
the risk of losing relevant information. Among patients placed in the illicit drug group, for 
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example, possible differences between the users of cannabis and amphetamines may not have 
been discovered. In addition, the grouping was based on a single laboratory test, which may 
be insensitive for the severity of substance use problems. Among patients with no drugs 
detected, for example, nearly half had AUDIT scores above cut-off. Furthermore, most 
patients do not belong to one specific drug group over time, as illustrated by readmitted 
patients who were represented in two different groups.  
 The greatest strength of this study was the comprehensive laboratory analyses used for the 
identification of substances in the blood and urine of these patients. This enabled a thorough 
investigation of detection rates, polydrug use and nonprescribed use of medicinal drugs. The 
use of advanced laboratory methods identifies cases of substance use missed by less sensitive 
tests (15) or by patients’ under-reporting (7, 30).  
 Given the high rates of substance use and the important clinical associations, drug 
screening seems warranted in acute psychiatric settings. Biometric and psychometric 
measures of substance use have complementary roles, and future studies are needed to define 
the proper way of combining these measures in acute psychiatric settings. Even a short 
hospitalization provides an excellent opportunity for identifying patients with or at risk for 
substance-related problems that may benefit from tailored interventions. 
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Table 1. Substances detected in blood and/or urine among 298 acute psychiatric admissions and according to 
different drug groups. 
 
  
 
 
 
All admissions 
n = 298 
(100%) (95% CI) 
 
Admissions with positive findings, n = 187 
 Medicinal 
drugs only 
n = 76 
(100%) 
Alcohol without 
illicit drugs 
n = 27 
(100%) 
Illicit 
drugs 
n = 84 
(100%) 
Median number of drugs (range) 1 (0-10) -  1 (1-5) 1 (1-4) 2 (1-10) 
Medicinal drugs* 138 (46%) (41-52%)  76 (100%) 12 (44%) 50 (60%) 
    Benzodiazepines  129 (43%) (38-49%)  72 (95%) 12 (44%) 45 (54%) 
        Diazepam or metabolites 101 (34%) (29-39%)  55 (72%) 10 (37%) 36 (43%) 
        Flunitrazepam 19 (6%) (4-9%)  3 (4%) 0 (0%) 16 (19%) 
        Clonazepam 34 (11%) (8-15%)  12 (16%) 3 (11%) 18 (21%) 
        Nitrazepam 33 (11%) (8-15%)  19 (25%) 2 (7%) 13 (16%) 
    Opiates or opioides 34 (11%) (8-15%)  12 (16%) 1 (4%) 21 (25%) 
        Morphine 24 (8%) (5-11%)  8 (11%) 1 (4%) 15 (18%) 
        Methadone 10 (3%) (1-5%)  1 (1%) 0 (0%) 9 (11%) 
Nonprescribed medicinal drugs† 108 (36%)  (31-42%)  50 (66%) 12 (44%) 46 (55%) 
    Benzodiazepines (nonprescr.) 91 (31%) (25-36%)  42 (55%) 11 (41%) 38 (45%) 
        Diazepam (nonprescr.) 58 (20%) (15-24%)  25 (33%) 10 (37%) 23 (27%) 
        Flunitrazepam (nonprescr.) 16 (5%) (3-8%)  2 (3%) 0 (0%) 14 (17%) 
Alcohol 37 (12%) (9-16%)  0 (0%) 27 (100%) 10 (12%) 
Illicit drugs‡ 84 (28%) (23-33%)  0 (0%) 0 (0%) 84 (100%) 
 
 
 
Values given in n (%) for dichotomous variables and median (range) for continuous variables. 
*Including hypnotica (zopiclone or zolpidem, n = 19), alprazolam (n = 3), carisoprodol (n = 1), meprobamate (n 
= 5), codeine (n = 16), buprenorphine (n = 2) and dextropropoxyfene (n = 1).  
†Detection of one or more nonprescribed medicinal drug (25 patients admitted nonprescribed use and in another 
83 admissions, the laboratory findings could not be documented in medical records).  
‡Amphetamines (n = 47), cannabis (n = 55), cocaine (n = 6) phenazepam (n = 3), 6-MAM (metabolite of heroin) 
(n = 2).  
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Table 2. Clinical characteristics according to different drug groups among 298 acute psychiatric admissions. 
 
   Admissions with positive findings, 
n = 187 
   
  
No drugs 
detected 
n = 111 
(100%) 
  
Medicinal 
drugs only 
n = 76 
(100%) 
Alcohol 
w/o illicit 
drugs 
n = 27 
(100%) 
 
Illicit 
drugs 
n = 84 
(100%) 
  
 
 
 
²  
 
 
 
 
P 
  
Data from medical records (n = 298)         
    Involuntary admission 70 (63%)  27 (36%) 11 (41%) 57 (68%)  22.407 <0.001 
    Suicidal risk score 2.5 (1.5)  3.0 (1.6) 3.4 (1.2) 2.3 (1.5)  5.294* 0.001 
    Coercive measures‡ 30 (27%)  5 (7%) 1 (4%) 32 (39%)  29.745 <0.001 
    Length of stay in days 9 (0-95)  10 (0-111) 1 (0-51) 4 (0-69)  22.878† <0.001 
    Transfer to long-term inpatient care 30 (27%)  14 (18%) 1 (4%) 6 (7%)  17.092 0.001 
    Discharge diagnoses (ICD-10)§         
        F1 Substance use disorders 16 (14%)  25 (33%) 20 (74%) 72 (86%)  112.093 <0.001 
            F10 Alcohol 9 (8%)  12 (16%) 16 (59%) 11 (13%)  43.032 <0.001 
            F19 Multiple substances 5 (5%)  4 (5%) 4 (15%) 47 (56%)  94.808 <0.001 
        F2 Schizophrenia 43 (39%)  17 (22%) 1 (4%) 16 (19%)  19.042 <0.001 
        F3 Affective disorders 39 (35%)  34 (45%) 10 (37%) 19 (23%)  8.892 0.031 
    Readmission in project period  18 (16%)  21 (28%) 9 (33%) 30 (36%)  10.452 0.015 
Physician on call (n = 285)         
    Positive symptoms (PANSS)¶ 18 (9)  14 (7) 12 (5) 20 (9)  9.082* <0.001 
    GAF – symptoms 36 (12)  37 (12) 39 (11) 32 (11)  3.291* 0.021 
    GAF – functioning 37 (13)  37 (9) 42 (10) 32 (9)  6.922* 0.001 
    Substance-related admission 22 (21%)  18 (25%) 24 (92%) 65 (80%)  110.311 <0.001 
Patient self-report (n = 230)         
    Substance-related admission 20 (23%)  10 (16%) 20 (87%) 47 (76%)  78.965 <0.001 
    -off on AUDIT 39 (45%)  19 (31%) 23 (100%) 34 (59%)  34.755 <0.001 
    -off on DUDIT 16 (19%)  9 (15%) 7 (30%) 46 (78%)  68.966 <0.001 
    Need for help with alcohol use 12 (14%)  6 (10%) 13 (57%) 14 (24%)  26.184 <0.001 
    Need for help with drug use 4 (5%)  8 (13%) 3 (14%) 29 (48%)  44.606 <0.001 
 
 
 
Values given in n (%) for dichotomous variables and mean (SD) or median (range) for continuous variables.  
2 tests were performed unless otherwise indicated, df = 3. P-values are given for comparisons among all drug 
groups. Values < 0.002 remain significant with Bonferroni correction. Variables that differed significantly after 
post-hoc pair wise comparisons are bold.  
*F-value from analysis of variance (ANOVA), †Kruskal-Wallis test.  
‡Seclusion (n = 61), coercive medication (n = 23) and manual restraints (n = 19).  
§Stated as primary or secondary diagnosis at discharge. Other diagnostic groups were F4 neurotic disorders (n = 
39) and F6 personality disorders (n = 53), whereas F0, F7 and F9 were rare (n < 10). 
¶Positive and negative syndrome scale, positive subscale: Agitation, hostility, suspiciousness, delusions, thought 
disturbances, hallucinations and grandiosity; assessed on a scale from 0 - 7, with increasing severity.                     
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